<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Surg</journal-id><journal-id journal-id-type="iso-abbrev">Int J Surg</journal-id><journal-id journal-id-type="pmc-domain-id">2035</journal-id><journal-id journal-id-type="pmc-domain">lwwopen</journal-id><journal-id journal-id-type="publisher-id">JS9</journal-id><journal-title-group><journal-title>International Journal of Surgery (London, England)</journal-title></journal-title-group><issn pub-type="ppub">1743-9191</issn><issn pub-type="epub">1743-9159</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Lippincott Open Access</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12430872</article-id><article-id pub-id-type="pmcid-ver">PMC12430872.1</article-id><article-id pub-id-type="pmcaid">12430872</article-id><article-id pub-id-type="pmcaiid">12430872</article-id><article-id pub-id-type="pmid">40497786</article-id><article-id pub-id-type="doi">10.1097/JS9.0000000000002733</article-id><article-id pub-id-type="publisher-id">IJS-D-24-06679</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" article-version-type="Version of Record">3</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Tumour Marker Prognostic Study</subject></subj-group></article-categories><title-group><article-title>Intratumoral IL-33<sup>+</sup>CD4<sup>+</sup>FoxP3<sup>+</sup> regulatory T cell infiltration determines poor clinical outcomes and intensive immunoevasive contexture in patients with pancreatic cancer after surgical resection: a cohort study</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3123-493X</contrib-id><name name-style="western"><surname>Pu</surname><given-names initials="N">Ning</given-names></name><degrees>MD, PhD</degrees><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref><xref rid="COR0001" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chen</surname><given-names initials="Q">Qiangda</given-names></name><degrees>MD, PhD</degrees><email>qdchen18@fudan.edu.cn</email><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>c</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Han</surname><given-names initials="J">Jiande</given-names></name><degrees>MBBS</degrees><email>21301050252@m.fudan.edu.cn</email><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Xu</surname><given-names initials="Z">Zhihang</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jiang</surname><given-names initials="Z">Zhenlai</given-names></name><degrees>MD</degrees><email>19301050227@fudan.edu.cn</email><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>He</surname><given-names initials="T">Taochen</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>An</surname><given-names initials="Y">Yanfei</given-names></name><degrees>PhD</degrees><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Xu</surname><given-names initials="Y">Yaolin</given-names></name><degrees>MD, PhD</degrees><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gan</surname><given-names initials="W">Wei</given-names></name><degrees>MD, PhD</degrees><email>gan.wei1@zs-hospital.sh.cn</email><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="H">Haibo</given-names></name><degrees>MD, PhD</degrees><email>Whbosy@163.com</email><xref rid="aff4" ref-type="aff">
<sup>d</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="W">Wenquan</given-names></name><degrees>MD, PhD</degrees><email>wang.wenquan@zs-hospital.sh.cn</email><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wu</surname><given-names initials="W">Wenchuan</given-names></name><degrees>MD, PhD</degrees><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jin</surname><given-names initials="Y">Yun</given-names></name><degrees>MD, PhD</degrees><email>colourcloud@126.com</email><xref rid="aff5" ref-type="aff">
<sup>e</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yu</surname><given-names initials="J">Jun</given-names></name><degrees>MD, PhD</degrees><xref rid="aff6" ref-type="aff">
<sup>f</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lou</surname><given-names initials="W">Wenhui</given-names></name><degrees>MD, PhD</degrees><email>lou.wenhui@zs-hospital.sh.cn</email><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref><xref rid="COR0001" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yin</surname><given-names initials="H">Hanlin</given-names></name><degrees>MD, PhD</degrees><email>20111210103@fudan.edu.cn</email><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref><xref rid="COR0001" ref-type="corresp">*</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Liu</surname><given-names initials="L">Liang</given-names></name><degrees>MD, PhD</degrees><email>liu.liang@zs-hospital.sh.cn</email><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref><xref rid="COR0001" ref-type="corresp">*</xref></contrib><aff id="aff1"><label>a</label>Department of Pancreatic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China</aff><aff id="aff2"><label>b</label>Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China</aff><aff id="aff3"><label>c</label>Department of Hepatobiliary Pancreatic Surgery, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China</aff><aff id="aff4"><label>d</label>Institute of Translational Medicine, Medical College, Yangzhou University, Yangzhou, China
</aff><aff id="aff5"><label>e</label>Department of Hepatobiliary and Pancreatic Surgery, The First People&#8217;s Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, China</aff><aff id="aff6"><label>f</label>Pancreas Center, Tianjin Medical University Cancer Institute &amp; Hospital, Tianjin Medical University, Tianjin, China</aff></contrib-group><author-notes><corresp id="COR0001"><label>*</label>Corresponding authors. Address: Department of Pancreatic Surgery, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China. Tel.: +86 021-64041990-2357. E-mail: <email>liu.liang@zs-hospital.sh.cn</email> (L. Liu); E-mail: <email>20111210103@fudan.edu.cn</email> (H. Yin); E-mail: <email>lou.wenhui@zs-hospital.sh.cn</email> (W. Lou); E-mail: <email>npu15@fudan.edu.cn</email> (N. Pu).</corresp></author-notes><pub-date pub-type="collection"><month>9</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>10</day><month>6</month><year>2025</year></pub-date><volume>111</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">496813</issue-id><fpage>6245</fpage><lpage>6259</lpage><history><date date-type="received"><day>27</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>01</day><month>6</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>12</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>13</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-13 17:25:36.317"><day>13</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 The Author(s). Published by Wolters Kluwer Health, Inc.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">Creative Commons Attribution-Non Commercial License 4.0</ext-link> (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="js9-111-6245.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="js9-111-6245.pdf"/><abstract><sec><title>Background:</title><p>Interleukin-33 (IL-33), a member of the IL-1 cytokine family, is constitutively expressed in barrier cells such as endothelial cells and fibroblasts. While the expression of IL-33 in regulatory T cells (Tregs) has been previously reported, its clinical significance in pancreatic ductal adenocarcinoma (PDAC) remains unclear. This study aims to investigate the clinical relevance and biological role of IL-33<sup>+</sup> Tregs in PDAC.</p></sec><sec><title>Methods:</title><p>Infiltration of IL-33<sup>+</sup> Tregs was assessed by immunohistochemistry in 215 patients from our institute. The correlation between IL-33<sup>+</sup> Tregs and clinical characteristics was analyzed. Additionally, the functional status of cytotoxic T cells in relation to IL-33<sup>+</sup> Treg infiltration was examined. The impact of IL-33<sup>+</sup> Tregs on the tumor microenvironment (TME) was further evaluated both <italic toggle="yes">in silico</italic> and <italic toggle="yes">in vitro</italic>.</p></sec><sec><title>Results:</title><p>IL-33<sup>+</sup> Tregs infiltration was confirmed in PDAC tissues, and its abundance was positively associated with microvascular invasion, perineural invasion, and elevated serum CA19-9 levels. Patients with higher tumor-infiltrating IL-33<sup>+</sup> Tregs demonstrated poorer overall survival (OS) and recurrence-free survival (RFS) compared to those with lower infiltration levels. Multivariate analysis confirmed IL-33<sup>+</sup> Tregs as an independent prognostic factor for both OS and RFS, with improved survival prediction when combined with tumor differentiation. Subgroup analyses indicated that serum CA19-9 was not a useful risk stratification tool in patients with high IL-33<sup>+</sup> Treg infiltration, and these patients showed limited survival benefit from adjuvant chemotherapy. Furthermore, increased IL-33<sup>+</sup> Treg infiltration was associated with more pronounced immunosuppressive TME, marked by a reduction in cytotoxic phenotypes and an upregulation of exhausted markers on CD8<sup>+</sup> T cells.</p></sec><sec><title>Conclusion:</title><p>Our findings identify IL-33<sup>+</sup> Tregs as a novel subtype of Tregs, with strong prognostic value for survival risk stratification and therapeutic response prediction in PDAC. IL-33<sup>+</sup> Tregs exhibit more pronounced immunosuppressive capabilities, impairing CD8<sup>+</sup> T cell function. With further investigation, IL-33<sup>+</sup> Tregs may represent a promising immunotherapeutic target for PDAC.</p></sec></abstract><kwd-group><kwd>IL-33</kwd><kwd>immunotherapy</kwd><kwd>pancreatic ductal adenocarcinoma</kwd><kwd>prognosis</kwd><kwd>regulatory T cells</kwd><kwd>tumor microenvironment</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>SDC</meta-name><meta-value>T</meta-value></custom-meta><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Pancreatic ductal adenocarcinoma (PDAC) is among the most deadly cancers, with a 5-year survival rate below 13%, despite advances in surgery, chemotherapy, and radiotherapy<sup>[<xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R2" ref-type="bibr">2</xref>]</sup>. The aggressive nature of PDAC is largely driven by its distinctive tumor microenvironment (TME), which is marked by a dense fibrotic stroma and a strongly immunosuppressive setting that promotes tumor growth and metastasis<sup>[<xref rid="R3" ref-type="bibr">3</xref>,<xref rid="R4" ref-type="bibr">4</xref>]</sup>. Immune cells within this TME, including regulatory T cells (Tregs), myeloid-derived suppressor cells, and tumor-associated macrophages (TAMs), are key players in dampening anti-tumor responses and enabling immune evasion<sup>[<xref rid="R5" ref-type="bibr">5</xref>]</sup>.</p><p>The transcription factor Foxp3, which is encoded by an X chromosome-linked gene and exhibits lineage specificity, is primarily expressed in CD4<sup>+</sup>CD25<sup>+</sup> T lymphocytes. Foxp3 is both necessary and sufficient for the development and suppressive function of CD4<sup>+</sup>CD25<sup>+</sup> Tregs<sup>[<xref rid="R6" ref-type="bibr">6</xref>]</sup>. Consequently, CD4<sup>+</sup>CD25<sup>+</sup> T cells exhibiting Foxp3 expression and immunosuppressive activity are now defined as Tregs. Tregs are essential for maintaining immune balance by controlling excessive immune reactions. In cancers, however, Tregs often shift this function towards supporting immune tolerance of tumors, thereby aiding disease progression<sup>[<xref rid="R7" ref-type="bibr">7</xref>]</sup>. In PDAC, higher levels of Treg infiltration have been linked to worse outcomes and resistance to immunotherapy, as shown in our previous studies<sup>[<xref rid="R8" ref-type="bibr">8</xref>,<xref rid="R9" ref-type="bibr">9</xref>]</sup>. Recent research has identified a subset of Tregs that express interleukin-33 (IL-33), which appears to create an even more suppressive immune environment<sup>[<xref rid="R10" ref-type="bibr">10</xref>]</sup>.</p><p>IL-33, a member of the interleukin-1 (IL-1) family due to structural similarities, is constitutively expressed in barrier cells, such as endothelial cells, epithelial cells, and stromal fibroblasts<sup>[<xref rid="R11" ref-type="bibr">11</xref>,<xref rid="R12" ref-type="bibr">12</xref>]</sup>. However, without a secretory export sequence, nuclear IL-33 can be passively released by damaged membranes during non-lethal events like cellular stretch<sup>[<xref rid="R13" ref-type="bibr">13</xref>]</sup>, oxidative stress, or necrosis<sup>[<xref rid="R14" ref-type="bibr">14</xref>]</sup>. This characteristic led to IL-33 being classified as an &#8220;alarmin&#8221; cytokine, similar to IL-1&#945;. Additionally, IL-33 can be secreted into the extracellular environment in response to calcium influx triggered by Adenosine Triphosphate (ATP) or purinergic receptor signaling, confirming its role as a traditional cytokine, not merely an alarmin<sup>[<xref rid="R15" ref-type="bibr">15</xref>]</sup>. Secreted IL-33 promotes tumor proliferation and invasion by directly targeting tumor cells and supporting angiogenesis through activation of endothelial cells via the suppression of tumorigenicity 2 (ST2) receptor. It also shapes the TME by activating various immune cells, including T cells, basophils, macrophages, eosinophils, and type 2 innate lymphoid cells through ST2 signaling. Both na&#239;ve and regulatory CD4<sup>+</sup> T cells express ST2, making them targets of IL-33. Previous studies have shown that IL-33/ST2 signaling recruits GATA3<sup>+</sup> Tregs, enhancing the immunosuppressive environment<sup>[<xref rid="R16" ref-type="bibr">16</xref>]</sup>. More recent findings suggest that disrupting IL-33, rather than ST2, leads to tumor regression by inducing a &#8220;fragile&#8221; Treg phenotype through regulation of FoxP3 homeostasis<sup>[<xref rid="R10" ref-type="bibr">10</xref>]</sup>.</p><p>Given the pivotal role of Tregs and IL-33 in shaping an immunosuppressive TME in PDAC, it is essential to investigate their contributions to the poor clinical outcomes associated with this cancer. The specific impact of IL-33<sup>+</sup> Tregs in PDAC remains inadequately studied. These cells might not only signify a more aggressive tumor phenotype but also reveal how the tumor manipulates its immune environment to support its growth and spread. This paper seeks to clarify the prognostic significance of tumor-infiltrating IL-33<sup>+</sup> Tregs and their immunosuppressive characteristics. Additionally, it will explore potential therapeutic strategies aimed at targeting this pathway to improve anti-tumor immune responses.<boxed-text id="UBT0001" position="float" orientation="portrait"><sec><title>HIGHLIGHTS</title><p>
<list list-type="bullet"><list-item><p>Tumor-infiltrating IL-33<sup>+</sup> Tregs emerged as a distinct subtype of Tregs with significant prognostic implications in PDAC.</p></list-item><list-item><p>The presence of tumor-infiltrating IL-33<sup>+</sup> Tregs provides a robust framework for survival risk stratification and predicting therapeutic responses, particularly to adjuvant chemotherapy, thereby aiding in personalized and precision medicine.</p></list-item><list-item><p>IL-33<sup>+</sup> Tregs exhibit a more pronounced immunosuppressive capabilities in PDAC, impairing CD8<sup>+</sup> T cell function, which underscores the potential as an appealing target for future immunotherapy strategies.</p></list-item></list></p></sec></boxed-text></p></sec><sec sec-type="methods"><title>Methods and materials</title><sec><title>Study cohort and tissue microarray</title><p>This study utilized two previously mentioned tissue microarray (TMA) cohorts. The first cohort, collected from March 2015 to July 2018 at our institute, included 192 patients with pathologically confirmed PDAC who underwent radical resection. Six patients were excluded due to poor-quality tissue spots<sup>[<xref rid="R17" ref-type="bibr">17</xref>]</sup>. The second cohort, from September 2018 to October 2019, consisted of 29 additional PDAC patients, which was further incorporated into analysis<sup>[<xref rid="R9" ref-type="bibr">9</xref>]</sup>. The inclusion and exclusion criteria for both cohorts were as follows: (1) histologically confirmed PDAC with complete R0 resection; (2) complete clinical and follow-up data available; (3) no history of other primary malignancies; (4) no preoperative neoadjuvant therapies or involvement in clinical trials with immune or targeted therapies; (5) no evidence of distant metastasis. The protocol was registered in Research Registry (researchregistry11246).</p><p>Tumor tissues were fixed in formalin and embedded in paraffin. Representative tumor areas, selected by an experienced pathologist, were cut into 2.0 mm diameter cylindrical samples for TMA production. Clinicopathological data &#8211; including age, sex, surgical procedure, preoperative serum carbohydrate antigen 19-9 (CA19-9) levels, American Joint Committee on Cancer (AJCC) eighth edition of TNM stage, tumor differentiation, microvascular and perineural invasion, postoperative adjuvant radiotherapy (ART) and chemotherapy (ACT), and follow-up data &#8211; were collected by one surgeon and verified by another. This study has been reported in line with the STROCSS guidelines<sup>[<xref rid="R18" ref-type="bibr">18</xref>]</sup>.</p></sec><sec><title>Survival follow-up</title><p>The last follow-up date of this study was conducted in February 2024. All patients were regularly monitored following surgical resection, as previously described<sup>[<xref rid="R17" ref-type="bibr">17</xref>]</sup>. Overall survival (OS) was defined as the period from the date of surgery to death from any cause, or the last follow-up, whichever came first. Recurrence-free survival (RFS) was measured from the date of surgery to either the first instance of relapse or death, or the last follow-up. These definitions align with those used in our previous reports<sup>[<xref rid="R17" ref-type="bibr">17</xref>,<xref rid="R19" ref-type="bibr">19</xref>]</sup>.</p></sec><sec><title>Immunofluorescence staining and assessment</title><p>Formalin-fixed, paraffin-embedded (FFPE) tissue specimens of the TMAs were subjected to immunofluorescence (IF) staining, following established protocols<sup>[<xref rid="R9" ref-type="bibr">9</xref>]</sup>. Anti-CD4 (Maxim, RMA-0620), anti-FoxP3 (Cell Signaling Technology, 98377), and anti-IL-33 (Proteintech, 12372-1-AP) antibodies were used to identify IL-33<sup>+</sup>CD4<sup>+</sup>FoxP3<sup>+</sup> Tregs. The antibodies were incubated with hydrated TMA sections overnight at 4&#176;C, followed by labeling with Alex Fluor 647, Alex Fluor 555, and Alex Fluor 488. Afterward, the slides were counterstained with DAPI for 5&#160;minutes. Following washing and mounting, the sections were scanned using a 3D HISTECH Pannoramic SCAN fluorescence scanner. For each spot, three independent and representative high-power fields (HPF) at 200&#215; magnification (0.305 mm<sup>2</sup> per field) were captured. The results were assessed and quantified as previously described<sup>[<xref rid="R17" ref-type="bibr">17</xref>]</sup>.</p></sec><sec><title>Flow cytometry</title><p>Freshly resected PDAC tissues were dissociated, and the isolated cells were stained with surface markers (CD45, CD4, and CD25) at 4&#176;C for 30&#160;minutes. The cells were then fixed using IC Fixation Buffer (eBioscience, 00-8222-49). After three washes with PBS, the cells were permeabilized with Permeabilization Buffer (eBioscience, 00-8333-56) and stained for intracellular markers (FoxP3 and IL-33). Data acquisition was conducted using the BD FACS Arial Flow Cytometer (BD Biosciences, USA), and data analysis was performed with FlowJo V.10 software (BD Biosciences, USA). The antibodies used in this study included FITC anti-human CD4 (Biolegend, 317408), APC/Cyanine7 anti-human CD25 (Biolegend, 302613), Alexa Fluor 647 anti-human FOXP3 (Biolegend, 320213), PE anti-human IL-33 (Invitrogen, MA5-40993), and PerCP/Cyanine 5.5 anti-human CD45 (Biolegend, 304027).</p><p>In our previous study, we dissociated sixteen fresh PDAC tissues and analyzed tumor-infiltrating CD8<sup>+</sup> T cells for cytotoxic markers (TNF-&#945;, IFN-&#947;, Granzyme B, and Perforin) and exhaustion markers (PD-1, CTLA-4, TIM-3, and TIGIT)<sup>[<xref rid="R17" ref-type="bibr">17</xref>]</sup>. For the current study, FFPE slides from these cases were further used for IF staining of IL-33<sup>+</sup> Tregs. After quantifying the tumor-infiltrating IL-33<sup>+</sup> Tregs, the cases were divided into two cohorts based on their levels. Correlation analysis was then conducted to evaluate the potential immunomodulatory effects of IL-33<sup>+</sup> Tregs on CD8<sup>+</sup> T cells.</p><p>In addition, we dissociated eight fresh PDAC tissues and sorted Tregs as CD4<sup>high</sup>CD25<sup>high</sup>CD127<sup>low</sup> by MACS Treg magnetic separation (Miltenyi Biotec, 130-109-557) kit according to manufacturer instruction. The proportion of IL-33<sup>+</sup> Tregs was assessed by flow cytometry, and categorized into IL-33<sup>+</sup> Tregs high and low groups. These sorted Tregs were then co-cultured with CD8<sup>+</sup> T cells, which were amplified from healthy donor peripheral blood mononuclear cells (PBMCs), as previously described<sup>[<xref rid="R20" ref-type="bibr">20</xref>]</sup>. After co-culturing for 48&#160;hours, the cytotoxic profiles of CD8<sup>+</sup> T cells, including TNF-&#945;, IFN-&#947;, Granzyme B, and Perforin expression, were analyzed by flow cytometry.</p></sec><sec><title>Bioinformatic analysis</title><p>Transcriptomic and survival data for patients with PDAC were obtained from public databases, including the Cancer Genome Atlas (TCGA, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://cancergenome.nih.gov/" ext-link-type="uri">https://cancergenome.nih.gov/</ext-link>), the International Cancer Genome Consortium (ICGC, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://dcc.icgc.org/" ext-link-type="uri">https://dcc.icgc.org/</ext-link>), and the NIH GEO database (Accession #<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE71729">GSE71729</ext-link>). These datasets were analyzed to assess the prognostic significance and immunoregulatory function of IL-33<sup>+</sup> Tregs. Using a Treg-specific gene set from MSigDB (GSE22045_Treg_VS_TCONV_UP) combined with the IL-33 gene, we developed an IL-33<sup>+</sup> Treg signature. The GSVA algorithm was employed to calculate an IL-33<sup>+</sup> Treg score for each patient, with individuals stratified into high- and low-infiltration groups based on the optimal threshold, determined using the &#8220;surv_cutpoint&#8221; function from the &#8220;survminer&#8221; R package. Differentially expressed genes were identified within the ICGC dataset using the &#8220;limma&#8221; package, and ranked by log<sub>2</sub> fold change (log<sub>2</sub>FC). To explore the biological processes associated with different levels of IL-33<sup>+</sup> Treg infiltration, Gene Set Enrichment Analysis (GSEA) was performed based on Gene Ontology biological processes.</p></sec><sec><title>Statistical analysis</title><p>All statistical analyses were conducted using SPSS 21.0 and R version 4.3.0. Receiver operating characteristic (ROC) curve analysis was used to determine optimal cut-off values for continuous variables, including CA19-9 levels, total tumor-infiltrating Tregs, and IL-33<sup>+</sup> Tregs. Associations between tumor-infiltrating Treg cells (total and IL-33<sup>+</sup>) and clinicopathological characteristics were assessed using Pearson&#8217;s chi-square or Fisher&#8217;s exact tests, depending on the data distribution. For continuous variables, comparisons between groups were made using either Student&#8217;s <italic toggle="yes">t</italic>-test or the Mann&#8211;Whitney <italic toggle="yes">U</italic> test, as appropriate. Kaplan&#8211;Meier survival curves were generated and analyzed using log-rank tests. Independent prognostic factors for OS and RFS were identified through univariate and multivariate Cox proportional hazards analyses. Interaction analyses were performed using Cox models adjusted for potential confounding factors. A <italic toggle="yes">P</italic> value of less than 0.05 was considered statistically significant.</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Demographical and clinicopathological characteristics</title><p>A total of 215 PDAC patients with comprehensive follow-up data were included in this study. The cohort was 63.7% male, with a median age of 64&#160;years (interquartile range [IQR]: 58&#8211;70). Pathological grading revealed 4 patients with well-differentiated tumors, 91 with moderately differentiated tumors, and 120 with poorly differentiated tumors. According to the AJCC TNM staging system (eighth edition), 104 patients (48.4%) were classified as stage I, 92 (42.8%) as stage II, and 19 (8.8%) as stage III. Most patients (75.8%) received ACT, while 17.2% received ART. The median pre-operative serum CA19-9 level was 135.7&#160;U/mL (IQR: 35.0&#8211;374.7). Additional clinicopathological details are provided in Supplemental Digital Content Table 1, available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://links.lww.com/JS9/E310" ext-link-type="uri">http://links.lww.com/JS9/E310</ext-link>.</p></sec><sec><title>Identification and correlations of tumor-infiltrating IL-33<sup>+</sup> Tregs with clinicopathological characteristics</title><p>The presence of IL-33<sup>+</sup>CD4<sup>+</sup>FoxP3<sup>+</sup> Tregs in the PDAC microenvironment was identified through triple-color IF staining (Fig. <xref rid="F1" ref-type="fig">1</xref>A) and flow cytometry (Supplemental Digital Content Figure 1, available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://links.lww.com/JS9/E309" ext-link-type="uri">http://links.lww.com/JS9/E309</ext-link>). In the TMA slices, the median count of tumor-infiltrating IL-33<sup>+</sup> Tregs was 5.7 cells per HPF (IQR: 3.0&#8211;9.0), while the median count of total conventional Tregs was 13.7 cells/HPF (IQR: 9.0&#8211;19.0) (Supplemental Digital Content Table 1, available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://links.lww.com/JS9/E310" ext-link-type="uri">http://links.lww.com/JS9/E310</ext-link>). Flow cytometry of fresh PDAC tissues revealed that made up a median proportion of 46.6% (IQR: 37.6%&#8211;52.6%) of total conventional Tregs (Fig. <xref rid="F1" ref-type="fig">1</xref>B).<fig position="float" id="F1" orientation="portrait"><label>Figure 1.</label><caption><p>The presence, clinicopathological correlation, and prognostic significance of tumor-infiltrating IL-33<sup>+</sup> Tregs in the Zhongshan cohort. (A) Representative immunofluorescence staining images showing IL-33<sup>+</sup> and IL-33<sup>&#8722;</sup> Tregs in pancreatic cancer tissue. (B) Proportion of IL-33<sup>+</sup> Tregs in the total Treg population. (C&#8211;E) Tumor-infiltrating IL-33+&#160;Treg density comparisons in relation to different clinical parameters: microvascular invasion status, perineural invasion status, and serum CA19-9 levels. Statistical significance is indicated as ***<italic toggle="yes">P</italic> &lt; 0.001, ** <italic toggle="yes">P</italic> &lt; 0.01. (F, G) Kaplan&#8211;Meier plots depicting OS and RFS based on varying densities of tumor-infiltrating IL-33<sup>+</sup> Tregs via the log-rank test. OS refers to overall survival, RFS refers to recurrence-free survival.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="js9-111-6245-g001.jpg"/></fig>
</p><p>Based on ROC curve analysis, the optimal cut-off values were determined for serum CA19-9 (231.4&#160;U/mL), tumor-infiltrating conventional Tregs (13.2 cells/HPF), and tumor-infiltrating IL-33<sup>+</sup> Tregs (5.5 cells/HPF) as reported in our previous studies<sup>[<xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R17" ref-type="bibr">17</xref>]</sup>. Using these thresholds, patients were divided into low (104 patients) and high (111 patients) IL-33<sup>+</sup> Treg infiltration groups. Correlation analysis indicated that IL-33<sup>+</sup> Treg infiltration was significantly associated with serum CA19-9 levels (<italic toggle="yes">P</italic> =&#160;0.007), microvascular invasion (<italic toggle="yes">P</italic> =&#160;0.038), and perineural invasion (<italic toggle="yes">P</italic> &lt; 0.001), while other clinicopathological factors showed no significant associations (Table <xref rid="T1" ref-type="table">1</xref>). Tumors with microvascular invasion (<italic toggle="yes">P</italic> =&#160;0.006, Fig. <xref rid="F1" ref-type="fig">1</xref>C) or perineural invasion (<italic toggle="yes">P</italic> &lt; 0.001, Fig. <xref rid="F1" ref-type="fig">1</xref>D) exhibited notably higher IL-33<sup>+</sup> Tregs infiltration. Additionally, higher serum CA19-9 levels were predictive of increased IL-33<sup>+</sup> Tregs infiltration (<italic toggle="yes">P</italic> =&#160;0.002, Fig. <xref rid="F1" ref-type="fig">1</xref>E).<table-wrap position="float" id="T1" orientation="portrait"><label>Table 1</label><caption><p>The relationships between tumor-infiltrating Tregs and IL-33<sup>+</sup> Tregs and clinicopathological characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Variables</th><th align="center" rowspan="1" colspan="1">Low Tregs (<italic toggle="yes">n</italic> =&#160;101)</th><th align="center" rowspan="1" colspan="1">High Tregs (<italic toggle="yes">n</italic> =&#160;114)</th><th align="center" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th><th align="center" rowspan="1" colspan="1">Low IL-33<sup>+</sup> Tregs (<italic toggle="yes">n</italic> =&#160;104)</th><th align="center" rowspan="1" colspan="1">High IL-33<sup>+</sup> Tregs (<italic toggle="yes">n</italic> =&#160;111)</th><th align="center" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Sex</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.919</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.836</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Male/female</td><td align="center" rowspan="1" colspan="1">64/37</td><td align="center" rowspan="1" colspan="1">73/41</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">67/37</td><td align="center" rowspan="1" colspan="1">70/41</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.481</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.423</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&lt;65/&#160;&#8805;&#160;65</td><td align="center" rowspan="1" colspan="1">58/43</td><td align="center" rowspan="1" colspan="1">60/54</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">60/44</td><td align="center" rowspan="1" colspan="1">58/53</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Surgery</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.776</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.718</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Whipple/DP/TP</td><td align="center" rowspan="1" colspan="1">57/43/1</td><td align="center" rowspan="1" colspan="1">63/48/3</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">58/45/1</td><td align="center" rowspan="1" colspan="1">62/46/3</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Differentiation</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.101</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.136</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;I/ II/III</td><td align="center" rowspan="1" colspan="1">4/43/54</td><td align="center" rowspan="1" colspan="1">0/48/66</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">4/44/56</td><td align="center" rowspan="1" colspan="1">0/47/64</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">T stage</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.478</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.828</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;T1/T2/T3</td><td align="center" rowspan="1" colspan="1">31/57/13</td><td align="center" rowspan="1" colspan="1">36/57/21</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">32/57/15</td><td align="center" rowspan="1" colspan="1">35/57/19</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">N stage</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.908</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.168</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;N0/N1/N2</td><td align="center" rowspan="1" colspan="1">62/30/9</td><td align="center" rowspan="1" colspan="1">67/37/10</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">68/26/10</td><td align="center" rowspan="1" colspan="1">61/41/9</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">TNM stage</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.998</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.316</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;I/II/III</td><td align="center" rowspan="1" colspan="1">49/43/9</td><td align="center" rowspan="1" colspan="1">55/49/10</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">55/39/10</td><td align="center" rowspan="1" colspan="1">49/53/9</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">CA19-9</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.070</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"><bold>0.007</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&lt;231.4/&#160;&#8805;&#160;231.4&#160;U/L</td><td align="center" rowspan="1" colspan="1">68/33</td><td align="center" rowspan="1" colspan="1">63/51</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">73/31</td><td align="center" rowspan="1" colspan="1">58/53</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">ART</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.389</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.746</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No/yes</td><td align="center" rowspan="1" colspan="1">86/15</td><td align="center" rowspan="1" colspan="1">92/22</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">87/17</td><td align="center" rowspan="1" colspan="1">91/20</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">ACT</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.534</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.065</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No/yes/unknown</td><td align="center" rowspan="1" colspan="1">10/77/14</td><td align="center" rowspan="1" colspan="1">16/86/12</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">7/84/13</td><td align="center" rowspan="1" colspan="1">19/79/13</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Microvascular invasion</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.239</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"><bold>0.038</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No/yes</td><td align="center" rowspan="1" colspan="1">86/15</td><td align="center" rowspan="1" colspan="1">90/24</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">91/13</td><td align="center" rowspan="1" colspan="1">85/26</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Perineural invasion</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"><bold>0.001</bold></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"><bold>&lt;0.001</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No/yes</td><td align="center" rowspan="1" colspan="1">33/68</td><td align="center" rowspan="1" colspan="1">15/99</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">36/68</td><td align="center" rowspan="1" colspan="1">12/99</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Tumor IL-33<sup>+</sup> Tregs</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"><bold>&lt;0.001</bold></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">/</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Low/high</td><td align="center" rowspan="1" colspan="1">88/13</td><td align="center" rowspan="1" colspan="1">16/98</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">/</td><td align="center" rowspan="1" colspan="1">/</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Tumor Tregs</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">/</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"><bold>&lt;0.001</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Low/high</td><td align="center" rowspan="1" colspan="1">/</td><td align="center" rowspan="1" colspan="1">/</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">88/16</td><td align="center" rowspan="1" colspan="1">13/98</td><td align="center" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>Bold values represent that the factors have significant difference (<italic toggle="yes">p</italic> &lt; 0.05).</p></fn></table-wrap-foot></table-wrap>
</p></sec><sec sec-type="subjects"><title>Prognostic value of tumor-infiltrating IL-33<sup>+</sup> Treg in PDAC patients</title><p>The median follow-up duration for this cohort was 72.0&#160;months (95% CI: 68.8&#8211;75.2). Median OS was 28.5&#160;months, while median RFS was 16.8&#160;months. The 1-, 3-, and 5-year OS rates were 81.2%, 43.1%, and 27.9%, respectively. Similarly, the 1, 3, and 5-year RFS rates were 59.7%, 26.2%, and 17.7%, respectively. Patients in the high tumor-infiltrating conventional Treg group had significantly shorter median OS (21.1 vs. 41.0&#160;months, <italic toggle="yes">P</italic> &lt; 0.001, hazard ratio [HR]&#160;=&#160;2.103, 95% CI: 1.534&#8211;2.883, Supplemental Digital Content Figure 2A, available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://links.lww.com/JS9/E309" ext-link-type="uri">http://links.lww.com/JS9/E309</ext-link>) and RFS (11.9 vs. 29.0&#160;months, <italic toggle="yes">P</italic> &lt; 0.001, HR&#160;=&#160;2.141, 95% CI: 1.537&#8211;2.894, Supplemental Digital Content Figure 2B, available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://links.lww.com/JS9/E309" ext-link-type="uri">http://links.lww.com/JS9/E309</ext-link>) compared to the low-infiltration group, consistent with our previous findings<sup>[<xref rid="R8" ref-type="bibr">8</xref>,<xref rid="R9" ref-type="bibr">9</xref>]</sup>. More pronounced differences were observed between the high and low tumor-infiltrating IL-33<sup>+</sup> Treg groups, with a median OS of 17.9&#160;months versus 56.4&#160;months (<italic toggle="yes">P</italic> &lt; 0.001, HR&#160;=&#160;3.436, 95% CI: 2.475&#8211;4.769, Fig. <xref rid="F1" ref-type="fig">1</xref>F) and a median RFS of 10.7&#160;months versus 32.9&#160;months (<italic toggle="yes">P</italic> &lt; 0.001, HR&#160;=&#160;3.280, 95% CI: 2.393&#8211;4.495, Fig. <xref rid="F1" ref-type="fig">1</xref>G).</p><p>Univariate Cox analysis identified several factors significantly associated with both OS and RFS, including tumor differentiation (both <italic toggle="yes">P</italic> =&#160;0.002), N stage (both <italic toggle="yes">P</italic> &lt; 0.001), TNM stage (both <italic toggle="yes">P</italic> &lt; 0.001), serum CA19-9 levels (both <italic toggle="yes">P</italic> &lt; 0.001), ACT (<italic toggle="yes">P</italic> =&#160;0.019 and <italic toggle="yes">P</italic> =&#160;0.012, respectively), perineural invasion (<italic toggle="yes">P</italic> =&#160;0.001 and <italic toggle="yes">P</italic> =&#160;0.005, respectively), tumor-infiltrating IL-33<sup>+</sup> Tregs (both <italic toggle="yes">P</italic> &lt; 0.001), and tumor-infiltrating conventional Tregs (both <italic toggle="yes">P</italic> &lt; 0.001) (Table <xref rid="T2" ref-type="table">2</xref>). In multivariate Cox analysis, independent prognostic factors for both OS and RFS were identified as N stage (<italic toggle="yes">P</italic> =&#160;0.022, HR&#160;=&#160;1.903, 95% CI: 1.096&#8211;3.303 and <italic toggle="yes">P</italic> =&#160;0.045, HR&#160;=&#160;1.690, 95% CI: 1.012&#8211;2.823, respectively), ACT (<italic toggle="yes">P</italic> &lt; 0.001, HR&#160;=&#160;0.309, 95% CI: 0.194&#8211;0.493 and <italic toggle="yes">P</italic> =&#160;0.018, HR&#160;=&#160;0.577, 95% CI: 0.366&#8211;0.908, respectively), and tumor-infiltrating IL-33<sup>+</sup> Tregs (<italic toggle="yes">P</italic> &lt; 0.001, HR&#160;=&#160;4.323, 95% CI: 2.514&#8211;7.436 and <italic toggle="yes">P</italic> &lt; 0.001, HR&#160;=&#160;4.170, 95% CI: 2.523&#8211;6.894, respectively). Additionally, tumor differentiation (<italic toggle="yes">P</italic> =&#160;0.031, HR&#160;=&#160;1.422, 95% CI: 1.033&#8211;1.956) and serum CA19-9 levels (<italic toggle="yes">P</italic> =&#160;0.009, HR&#160;=&#160;1.536, 95% CI: 1.111&#8211;2.124) were identified as independent risk indicators for RFS alone (Table <xref rid="T2" ref-type="table">2</xref>).<table-wrap position="float" id="T2" orientation="portrait"><label>Table 2</label><caption><p>Univariate and multivariate analysis of prognostic indicators associated with overall survival and recurrence-free survival</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Variables</th><th align="center" colspan="3" rowspan="1">Overall survival</th><th align="center" colspan="3" rowspan="1">Recurrence-free survival</th></tr><tr><th align="center" rowspan="1" colspan="1">Univariate <italic toggle="yes">P</italic> value</th><th align="center" rowspan="1" colspan="1">Multivariate <italic toggle="yes">P</italic> value</th><th align="center" rowspan="1" colspan="1">Multivariate HR (95% CI)</th><th align="center" rowspan="1" colspan="1">Univariate <italic toggle="yes">P</italic> value</th><th align="center" rowspan="1" colspan="1">Multivariate <italic toggle="yes">P</italic> value</th><th align="center" rowspan="1" colspan="1">Multivariate HR (95% CI)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Sex</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Male/female</td><td align="center" rowspan="1" colspan="1">0.329</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.535</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&lt;65/&#160;&#8805;&#160;65</td><td align="center" rowspan="1" colspan="1">0.438</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.293</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Surgery</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Whipple/DP/TP</td><td align="center" rowspan="1" colspan="1">0.610</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.555</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Differentiation</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;I +&#160;II/III</td><td align="center" rowspan="1" colspan="1"><bold>0.002</bold></td><td align="center" rowspan="1" colspan="1">0.078</td><td align="center" rowspan="1" colspan="1">1.364 (0.966&#8211;1.926)</td><td align="center" rowspan="1" colspan="1"><bold>0.002</bold></td><td align="center" rowspan="1" colspan="1"><bold>0.031</bold></td><td align="center" rowspan="1" colspan="1">1.422 (1.033&#8211;1.956)</td></tr><tr><td align="left" rowspan="1" colspan="1">T stage</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;T1/T2/T3</td><td align="center" rowspan="1" colspan="1">0.192</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.245</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">N stage</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;N0/N1/N2</td><td align="center" rowspan="1" colspan="1"><bold>&lt;0.001</bold></td><td align="center" rowspan="1" colspan="1"><bold>0.022</bold></td><td align="center" rowspan="1" colspan="1">1.903 (1.096&#8211;3.303)</td><td align="center" rowspan="1" colspan="1"><bold>&lt;0.001</bold></td><td align="center" rowspan="1" colspan="1"><bold>0.045</bold></td><td align="center" rowspan="1" colspan="1">1.690 (1.012&#8211;2.823)</td></tr><tr><td align="left" rowspan="1" colspan="1">TNM stage</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;I/II/III</td><td align="center" rowspan="1" colspan="1"><bold>&lt;0.001</bold></td><td align="center" rowspan="1" colspan="1">0.537</td><td align="center" rowspan="1" colspan="1">0.838 (0.479&#8211;1.467)</td><td align="center" rowspan="1" colspan="1"><bold>&lt;0.001</bold></td><td align="center" rowspan="1" colspan="1">0.645</td><td align="center" rowspan="1" colspan="1">0.884 (0.523&#8211;1.495)</td></tr><tr><td align="left" rowspan="1" colspan="1">CA19-9</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;&lt;231.4/&#160;&#8805;&#160;231.4&#160;U/L</td><td align="center" rowspan="1" colspan="1"><bold>&lt;0.001</bold></td><td align="center" rowspan="1" colspan="1">0.059</td><td align="center" rowspan="1" colspan="1">1.387 (0.988&#8211;1.947)</td><td align="center" rowspan="1" colspan="1"><bold>&lt;0.001</bold></td><td align="center" rowspan="1" colspan="1"><bold>0.009</bold></td><td align="center" rowspan="1" colspan="1">1.536 (1.111&#8211;2.124)</td></tr><tr><td align="left" rowspan="1" colspan="1">ART</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No/yes</td><td align="center" rowspan="1" colspan="1">0.604</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.725</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">ACT</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No/yes/unknown</td><td align="center" rowspan="1" colspan="1"><bold>0.019</bold></td><td align="center" rowspan="1" colspan="1"><bold>&lt;0.001<xref rid="tbl2-fn1" ref-type="table-fn">a</xref></bold></td><td align="center" rowspan="1" colspan="1">0.309 (0.194&#8211;0.493)</td><td align="center" rowspan="1" colspan="1"><bold>0.012</bold></td><td align="center" rowspan="1" colspan="1"><bold>0.018<xref rid="tbl2-fn1" ref-type="table-fn">a</xref></bold></td><td align="center" rowspan="1" colspan="1">0.577 (0.366&#8211;0.908)</td></tr><tr><td align="left" rowspan="1" colspan="1">Microvascular invasion</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No/yes</td><td align="center" rowspan="1" colspan="1">0.775</td><td align="center" rowspan="1" colspan="1">NA</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.475</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Perineural invasion</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;No/yes</td><td align="center" rowspan="1" colspan="1"><bold>0.001</bold></td><td align="center" rowspan="1" colspan="1">0.204</td><td align="center" rowspan="1" colspan="1">1.349 (0.850&#8211;2.140)</td><td align="center" rowspan="1" colspan="1"><bold>0.005</bold></td><td align="center" rowspan="1" colspan="1">0.386</td><td align="center" rowspan="1" colspan="1">1.201 (0.794&#8211;1.817)</td></tr><tr><td align="left" rowspan="1" colspan="1">Tumor IL-33<sup>+</sup> Tregs</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Low/high</td><td align="center" rowspan="1" colspan="1"><bold>&lt;0.001</bold></td><td align="center" rowspan="1" colspan="1"><bold>&lt;0.001</bold></td><td align="center" rowspan="1" colspan="1">4.323 (2.514&#8211;7.436)</td><td align="center" rowspan="1" colspan="1"><bold>&lt;0.001</bold></td><td align="center" rowspan="1" colspan="1"><bold>&lt;0.001</bold></td><td align="center" rowspan="1" colspan="1">4.170 (2.523&#8211;6.894)</td></tr><tr><td align="left" rowspan="1" colspan="1">Tumor Tregs</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Low/high</td><td align="center" rowspan="1" colspan="1"><bold>&lt;0.001</bold></td><td align="center" rowspan="1" colspan="1">0.056</td><td align="center" rowspan="1" colspan="1">0.615 (0.373&#8211;1.013)</td><td align="center" rowspan="1" colspan="1"><bold>&lt;0.001</bold></td><td align="center" rowspan="1" colspan="1">0.118</td><td align="center" rowspan="1" colspan="1">0.693 (0.437&#8211;1.098)</td></tr></tbody></table><table-wrap-foot><fn id="tbl2-fn1"><label><sup>a</sup></label><p>Bold values represent that the factors have significant difference (<italic toggle="yes">p</italic> &lt; 0.05).</p><p>Adjusted <italic toggle="yes">P</italic> value for receiving ACT compared to those not received.</p></fn></table-wrap-foot></table-wrap>
</p></sec><sec><title>Survival predictive value in combination of tumor-infiltrating IL-33<sup>+</sup> Tregs and tumor differentiation</title><p>Tumor differentiation, a key indicator of the tumor&#8217;s inherent aggressiveness, has long been recognized as a prognostic factor in PDAC<sup>[<xref rid="R21" ref-type="bibr">21</xref>]</sup>. Our interaction analysis demonstrated a significant association between tumor-infiltrating IL-33<sup>+</sup> Tregs and tumor differentiation, with both showing a strong correlation with OS and RFS (both <italic toggle="yes">p</italic> &lt; 0.001), after adjusting for confounding variables. These findings confirmed that both tumor-infiltrating IL-33<sup>+</sup> Tregs and tumor differentiation were independent prognostic indicators of RFS, which indicated that tumor-infiltrating IL-33<sup>+</sup> Tregs could serve as a crucial biomarker for tumor malignancy. By combining these two biological characteristics &#8211; tumor-infiltrating IL-33<sup>+</sup> Tregs and tumor differentiation &#8211; we achieved a more precise stratification of patient prognosis. The median OS for the subgroups defined by IL-33<sup>+</sup> Treg levels and tumor grades were as follows: 15.5&#160;months for IL-33<sup>+</sup> Treg<sup>high</sup> and G3, 26.3&#160;months for IL-33<sup>+</sup> Treg<sup>high</sup> and G1-2, 46.9&#160;months for IL-33<sup>+</sup> Treg<sup>low</sup> and G3, and not yet reached for IL-33<sup>+</sup> Treg<sup>low</sup> and G1-2 (Fig. <xref rid="F2" ref-type="fig">2</xref>A). The HRs for OS in the IL-33<sup>+</sup> Treg<sup>high</sup> and G3, IL-33<sup>+</sup> Treg<sup>high</sup> and G1-2 and IL-33<sup>+</sup> Treg<sup>low</sup> and G3 subgroups, using IL-33<sup>+</sup> Treg<sup>low</sup> and G1-2 as a reference, were 6.610, 3.912, and 1.727, respectively. Similarly, the median RFS for these subgroups was 9.0, 13.0, 28.3, and 41.4&#160;months, respectively (Fig. <xref rid="F2" ref-type="fig">2</xref>B), with corresponding HRs of 6.395, 4.088, and 1.762. These results demonstrate a stronger and more refined risk stratification when IL-33<sup>+</sup> Tregs are assessed alongside tumor differentiation, highlighting the interplay between malignant tumor biology and immunosuppressive TME.<fig position="float" id="F2" orientation="portrait"><label>Figure 2.</label><caption><p>Survival predictive value of combining intratumoral IL-33<sup>+</sup> Tregs with tumor differentiation. (A, B) Kaplan&#8211;Meier plots depicting OS and RFS based on the density of tumor-infiltrating IL-33<sup>+</sup> Tregs and tumor differentiation via the log-rank test. (C, D) Receiver operating characteristic curves for 1-, 3-, and 5-year OS and RFS, showing the predictive performance of IL-33<sup>+</sup> Tregs, tumor differentiation, and their combination. OS refers to overall survival, RFS refers to recurrence-free survival.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="js9-111-6245-g002.jpg"/></fig>
</p><p>Furthermore, the combined predictive model for 1-, 3-, and 5-year OS achieved area under the curve values of 0.745, 0.788, and 0.817, respectively, outperforming either factor alone (Fig. <xref rid="F2" ref-type="fig">2</xref>C). Decision curve analysis further underscored the greater net benefit of the combined model across a wider range of threshold probabilities when compared to tumor-infiltration IL-33<sup>+</sup> Tregs or tumor differentiation in isolation (Supplemental Digital Content Figure 3A, available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://links.lww.com/JS9/E309" ext-link-type="uri">http://links.lww.com/JS9/E309</ext-link>). Consistent results were observed for RFS (Fig. <xref rid="F2" ref-type="fig">2</xref>D and Supplemental Digital Content Figure 3B, available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://links.lww.com/JS9/E309" ext-link-type="uri">http://links.lww.com/JS9/E309</ext-link>). Therefore, these findings highlight the worst survival outcomes in patients with high IL-33<sup>+</sup> Treg levels and poorly differentiated tumors, emphasizing the predictive value of combining immunosuppressive and tumor biological features.</p></sec><sec><title>Prognostic variations of serum biological CA19-9 level intercepted by tumor-infiltrating IL-33<sup>+</sup> Tregs</title><p>CA19-9 is the most widely used tumor biomarker for PDAC and the only FDA-approved marker for diagnosis, assessing tumor burden, and monitoring therapeutic response. Numerous studies have validated its pre- and peri-operative prognostic value for patient outcomes<sup>[<xref rid="R22" ref-type="bibr">22</xref>,<xref rid="R23" ref-type="bibr">23</xref>]</sup>. In our subgroup analysis, adjusted for all confounding variables, interaction analysis revealed that the prognostic utility of serum CA19-9 may be influenced by the level of tumor-infiltrating IL-33<sup>+</sup> Tregs (both <italic toggle="yes">P</italic> &lt; 0.001 for OS and RFS). Specifically, in the low IL-33<sup>+</sup> Treg group, CA19-9 demonstrated strong predictive power. Patients with high CA19-9 levels had a significantly worse median OS compared to those with low levels (34.8 vs. NA. months, <italic toggle="yes">P</italic> &lt; 0.001, Fig. <xref rid="F3" ref-type="fig">3</xref>A) and a similarly worse RFS (20.6 vs. 48.6&#160;months, <italic toggle="yes">P</italic> &lt; 0.001, Fig. <xref rid="F3" ref-type="fig">3</xref>B). However, in the high IL-33<sup>+</sup> Treg group, CA19-9 levels did not significantly correlate with prognosis (OS: 16.7 vs. 20.8&#160;months, <italic toggle="yes">P</italic> =&#160;0.423, Fig. <xref rid="F3" ref-type="fig">3</xref>C; RFS: 10.0 vs. 11.5&#160;months, <italic toggle="yes">P</italic> =&#160;0.222, Fig. <xref rid="F3" ref-type="fig">3</xref>D). These results suggest that tumor-infiltrating IL-33<sup>+</sup> Treg play a critical role in modulating the predictive accuracy of CA19-9. These observations emphasize the dynamic crosstalk between the TME and intrinsic tumor biological behavior, implying that TME-mediated immunosuppression may exert dominant role in malignant progression.<fig position="float" id="F3" orientation="portrait"><label>Figure 3.</label><caption><p>Survival analysis based on intratumoral IL-33<sup>+</sup> Tregs infiltration level and serum CA19-9 level stratification. (A, B) Kaplan&#8211;Meier plots depicting OS and RFS in patients with low tumor-infiltrating IL-33<sup>+</sup> Tregs density according to serum CA19-9 levels via the log-rank test. (C, D) Kaplan&#8211;Meier plots depicting OS and RFS in patients with high tumor-infiltrating IL-33<sup>+</sup> Tregs density according to serum CA19-9 levels via the log-rank test. OS refers to overall survival, RFS refers to recurrence-free survival.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="js9-111-6245-g003.jpg"/></fig>
</p></sec><sec sec-type="subjects"><title>Therapeutic response to ACT in PDAC patients based on tumor-infiltrating IL-33<sup>+</sup> Tregs</title><p>Chemotherapy has been shown to influence the TME in PDAC<sup>[<xref rid="R24" ref-type="bibr">24</xref>]</sup>, while the TME, in turn, can affect chemotherapy efficacy<sup>[<xref rid="R25" ref-type="bibr">25</xref>,<xref rid="R26" ref-type="bibr">26</xref>]</sup>. Immune cells within the TME can either hinder or enhance therapeutic response by altering their patterns and functions<sup>[<xref rid="R27" ref-type="bibr">27</xref>]</sup>. Our interaction analysis, adjusted for confounding factors, revealed a significant relationship between tumor-infiltrating IL-33<sup>+</sup> Tregs and the impact of ACT on patient outcomes (both <italic toggle="yes">P</italic> &lt; 0.001 for OS and RFS). In patients with low IL-33<sup>+</sup> Treg infiltration, those receiving ACT had significantly longer OS (59.2 vs. 16.9&#160;months, <italic toggle="yes">P</italic> =&#160;0.002, Fig. <xref rid="F4" ref-type="fig">4</xref>A) and RFS (32.4 vs. 9.8&#160;months, <italic toggle="yes">P</italic> =&#160;0.012, Fig. <xref rid="F4" ref-type="fig">4</xref>B) compared to those who did not receive ACT. In the high IL-33<sup>+</sup> Treg subgroup, patients receiving ACT also had a longer OS compared to those without ACT (22.5 vs. 10.0&#160;months, <italic toggle="yes">P</italic> &lt; 0.001, Fig. <xref rid="F4" ref-type="fig">4</xref>C). However, while there was a significant difference in OS within the high IL-33<sup>+</sup> Treg subgroup, the OS benefit remained relatively limited. Meanwhile, no significant difference in RFS was observed between ACT and non-ACT groups in this subgroup (10.7 vs. 6.9&#160;months, <italic toggle="yes">P</italic> =&#160;0.123, Fig. <xref rid="F4" ref-type="fig">4</xref>D). These findings suggest that PDAC patients with high IL-33<sup>+</sup> Tregs infiltration may derive limited benefit from ACT, whereas those with lower IL-33<sup>+</sup> Treg levels are more likely to experience a favorable response to ACT.<fig position="float" id="F4" orientation="portrait"><label>Figure 4.</label><caption><p>Survival analysis based on intratumoral IL-33<sup>+</sup> Tregs infiltration and chemotherapy. (A, B) Kaplan&#8211;Meier plots depicting OS and RFS in patients with low tumor-infiltrating IL-33<sup>+</sup> Tregs according to adjuvant chemotherapy or not. (C, D) Kaplan&#8211;Meier plots depicting OS and RFS in patients with high tumor-infiltrating IL-33<sup>+</sup> Tregs according to adjuvant chemotherapy or not. Log-rank test was applied to Kaplan&#8211;Meier curves. OS refers to overall survival, RFS refers to recurrence-free survival.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="js9-111-6245-g004.jpg"/></fig>
</p></sec><sec><title>Tumor-infiltrating IL-33<sup>+</sup> Treg as a robust immunosuppressive phenotype in PDAC</title><p>To clarify the specific role of IL-33<sup>+</sup> Tregs in the PDAC microenvironment, we retrospectively assessed the level of tumor-infiltrating IL-33<sup>+</sup> Tregs in sixteen PDAC patients using their FFPE slides. In these patients, the activation and exhaustion profiles of tumor-infiltrating CD8<sup>+</sup> T cells had been previously analyzed through flow cytometry, as reported in our earlier study<sup>[<xref rid="R17" ref-type="bibr">17</xref>]</sup>. Representative images of high and low tumor-infiltrating IL-33<sup>+</sup> Tregs were displayed in Figure <xref rid="F5" ref-type="fig">5</xref>A. Intriguingly, patients with high IL-33<sup>+</sup> Treg infiltration exhibited significantly higher levels of CD8<sup>+</sup> T cell exhaustion markers, including TIM3 and PD-1, compared to those with low IL-33<sup>+</sup> Treg infiltration (Fig. <xref rid="F5" ref-type="fig">5</xref>B). Furthermore, the cytotoxic phenotype, indicated by GzmB expression in CD8<sup>+</sup> T cells, was markedly reduced in the high IL-33<sup>+</sup> Treg group (Fig. <xref rid="F5" ref-type="fig">5</xref>C).<fig position="float" id="F5" orientation="portrait"><label>Figure 5.</label><caption><p>Tumor-infiltrating IL-33<sup>+</sup> Tregs as a pronounced immunosuppressive phenotype in PDAC. (A) Representative images of high and low tumor-infiltration IL-33<sup>+</sup> Tregs in PDAC tissues. Flow cytometry to compare the levels of exhausted markers (B) and cytotoxic cytokines (C) in tumor-infiltrating CD8<sup>+</sup> T cells between IL-33<sup>+</sup> Tregs high and low groups. *<italic toggle="yes">P</italic> &lt; 0.05, **<italic toggle="yes">P</italic> &lt; 0.01, ***<italic toggle="yes">P</italic> &lt; 0.001, ns refers to not significant.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="js9-111-6245-g005.jpg"/></fig>
</p><p>To investigate the clinical impact of IL-33<sup>+</sup> Tregs, we applied an IL-33<sup>+</sup> Treg gene signature to stratify PDAC patients into high and low-infiltration groups using three independent transcriptomic datasets. In all datasets, patients with high IL-33<sup>+</sup> Treg infiltration had significantly worse OS, as demonstrated in the TCGA cohort (<italic toggle="yes">P</italic> &lt; 0.001, Fig. <xref rid="F6" ref-type="fig">6</xref>A), <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE71729">GSE71729</ext-link> cohort (<italic toggle="yes">P</italic> =&#160;0.035, Fig. <xref rid="F6" ref-type="fig">6</xref>B), and ICGC cohort (<italic toggle="yes">P</italic> =&#160;0.002, Fig. <xref rid="F6" ref-type="fig">6</xref>C). To further explore biological function of IL-33<sup>+</sup> Tregs in PDAC, we then conducted differential gene expression analysis between the high and low IL-33<sup>+</sup> Treg groups in these datasets. Genes related to extracellular matrix (ECM) remodeling, including collagen (FAP, COL11A1, COL17A1) and integrins (ITGB6, ITGA2), were significantly enriched in the high IL-33<sup>+</sup> Treg group. TGFB1, a critical cytokine for Treg differentiation, immunosuppression, and ECM remodeling, was also up-regulated in this group (Fig. <xref rid="F6" ref-type="fig">6</xref>D). GSEA revealed that pathways associated with cell cycle, DNA replication, Th17/IL-17 signaling, and TGF-&#946; production were significantly enriched in the high IL-33<sup>+</sup> Treg group. In contrast, pathways related to pancreatic secretion, digestion, and absorption were enriched in the low IL-33<sup>+</sup> Treg group (Fig. <xref rid="F6" ref-type="fig">6</xref>E). To validate the immunosuppressive properties of IL-33<sup>+</sup> Tregs, we isolated tumor-infiltrating Tregs from fresh PDAC tissues, quantified their proportions via flow cytometry, and co-cultured them with human PBMC-derived CD8<sup>+</sup> T cells, as previously described<sup>[<xref rid="R20" ref-type="bibr">20</xref>]</sup>. As anticipated, a high proportion of IL-33<sup>+</sup> Tregs significantly suppressed the cytotoxic phenotypes of CD8<sup>+</sup> T cells (Fig. <xref rid="F6" ref-type="fig">6</xref>F). In summary, IL-33<sup>+</sup> Tregs have a more pronounced capacity for immunosuppression, and appear to correlate with ECM remodeling, and tumor proliferation process in PDAC.<fig position="float" id="F6" orientation="portrait"><label>Figure 6.</label><caption><p>Validation of the prognostic value and biological function of IL-33<sup>+</sup> Tregs. (A&#8211;C) Kaplan&#8211;Meier plots depicting OS in patients with different IL-33<sup>+</sup> Treg infiltration level within the TCGA, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE71729">GSE71729</ext-link>, and ICGC cohort. (D) Volcano plot depicting the differentially expressed genes in IL-33<sup>+</sup> Tregs high groups compared to IL-33<sup>+</sup> Tregs low groups within the TCGA, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE71729">GSE71729</ext-link>, and ICGC cohorts. (E) Gene Set Enrichment Analysis (Go biological process) on genes ranked by log2 fold change between IL-33<sup>+</sup> Treg high and low groups within the TCGA, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE71729">GSE71729</ext-link>, and ICGC cohorts. (F) Flow cytometry analysis for amplified CD8<sup>+</sup> T cells cytotoxic phenotype after co-culturing with Tregs sorting from PDAC tissues. The proportion of IL-33<sup>+</sup> Tregs in each sample was evaluated immediately after sorting, and divided into IL-33<sup>+</sup> Tregs<sup>high</sup> (&gt;50%) and IL-33<sup>+</sup> Tregs<sup>low</sup> (&lt;50%) groups. OS refers to overall survival, TCGA refers to The Cancer Genome Atlas; ICGC refers to International Cancer Genome Consortium.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="js9-111-6245-g006.jpg"/></fig>
</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>IL-33, a cytokine from the IL-1 family, serves as a pivotal immunomodulatory factor that influences immune cells function within the TME. This study highlights the regulatory impact of IL-33<sup>+</sup> Tregs and their crucial role in survival stratification, promoting tumor progression, underscoring their contribution to immune evasion. Recent research has shown that IL-33 can originate from multiple sources, including tumor cells, stromal cells, and other immune cells within the TME, resulting in varied effects across different cancer types<sup>[<xref rid="R14" ref-type="bibr">14</xref>,<xref rid="R28" ref-type="bibr">28</xref>,<xref rid="R29" ref-type="bibr">29</xref>]</sup>. In line with these observations, our study demonstrates that IL-33<sup>+</sup> Tregs are not only strong predictors of prognosis and treatment outcomes in PDAC but also modulate the pronounced immunosuppression, further driving tumor growth and progression.</p><p>One key characteristic of IL-33 is its diverse origins. Alam <italic toggle="yes">et al</italic><sup>[<xref rid="R30" ref-type="bibr">30</xref>]</sup>. observed that IL-33 produced by tumor cells can recruit and activate TH2 cells and group 2 innate lymphoid cells, which then release tumor-promoting cytokines like IL-4, IL-5, and IL-13, driving tumor growth. In contrast, Alonso-Curbelo <italic toggle="yes">et al</italic><sup>[<xref rid="R31" ref-type="bibr">31</xref>]</sup>. linked IL-33 activation in Kras-mutant pancreatic epithelial cells to the combined effects of tissue damage and Kras mutations, which together trigger early epigenetic reprogramming and tumorigenesis. Hatzioannou <italic toggle="yes">et al</italic><sup>[<xref rid="R10" ref-type="bibr">10</xref>]</sup>. found that IL-33 is produced directly by Tregs within tumors, where it plays a crucial role in maintaining their stability and suppressive function. This intrinsic production of IL-33 by Tregs supports their immunosuppressive activity within the TME, aiding immune evasion. Additionally, IL-33 can be secreted by other cells such as fibroblasts, dendritic cells, and macrophages, contributing to its varied effects depending on the source<sup>[<xref rid="R32" ref-type="bibr">32</xref>&#8211;<xref rid="R34" ref-type="bibr">34</xref>]</sup>. In our study, we identified Tregs as one of the primary sources of IL-33, emphasizing their pivotal role in tumor immunosuppression. While CA19-9 maintains predictive value in PDAC patients with low IL-33<sup>+</sup> Treg infiltration, this correlation is abolished in those with high IL-33<sup>+</sup> Treg infiltration. This suggests that the immunosuppressive function of Tregs, rather than the tumor burden and malignant behavior, plays a dominant role in shaping the tumor&#8217;s progression and clinical outcomes.</p><p>IL-33 has been found to play a dual role in both promoting inflammation and driving immunosuppression within tumors. On the one hand, IL-33 enhances Treg proliferation and function through its receptor ST2, facilitating immune escape by tumors. Our study revealed that high infiltration of IL-33<sup>+</sup> Tregs is often accompanied by reduced cytotoxicity and enhanced exhaustion of CD8<sup>+</sup> T cells. These findings are consistent with previous research. Studies by Alam <italic toggle="yes">et al</italic> and Akimoto <italic toggle="yes">et al</italic> demonstrated that IL-33, through the ST2 receptor, fosters an immunosuppressive TME that supports tumor growth<sup>[<xref rid="R30" ref-type="bibr">30</xref>,<xref rid="R35" ref-type="bibr">35</xref>,<xref rid="R36" ref-type="bibr">36</xref>]</sup>. Additionally, macrophages have been shown to secrete TGF-&#946;, much like tumor-initiating cells, which induces invasive and drug-resistant properties while further increasing IL-33 expression<sup>[<xref rid="R29" ref-type="bibr">29</xref>,<xref rid="R37" ref-type="bibr">37</xref>]</sup>. This elevated IL-33 level promotes the differentiation of macrophages into an immunosuppressive phenotype<sup>[<xref rid="R35" ref-type="bibr">35</xref>,<xref rid="R38" ref-type="bibr">38</xref>]</sup>. On the other hand, IL-33&#8217;s pro-inflammatory role is evident in its ability to activate effector immune cells. For example, Song <italic toggle="yes">et al</italic><sup>[<xref rid="R39" ref-type="bibr">39</xref>]</sup> found that IL-33 enhanced CD8<sup>+</sup> T cell activity, contributing to anti-tumor immune responses. Dixit <italic toggle="yes">et al</italic><sup>[<xref rid="R40" ref-type="bibr">40</xref>]</sup> observed in a CCR2 gene knockout mouse model that reduced monocyte recruitment led to lower TNF-&#945; levels and increased IL-33 expression, which decreased metastasis and improved survival. In addition, Song <italic toggle="yes">et al</italic><sup>[<xref rid="R39" ref-type="bibr">39</xref>]</sup> showed that in colorectal cancer, IL-33 increased tumor sensitivity to 5-FU in the presence of T cells. However, most studies indicate that IL-33 predominantly exerts an immunosuppressive effect in tumors.</p><p>Treg cells are well known for their ability to suppress major inflammatory responses by regulating the activity of various cells in both the innate and adaptive immune systems<sup>[<xref rid="R41" ref-type="bibr">41</xref>]</sup>. Previous research has established that IL-33 activates several downstream pathways and engages in crosstalk with other cells, contributing to tumor progression. A consensus nuclear localization sequence in the N-terminus of IL-33 directs it to the cell nucleus (nIL-33), where it functions as a repressive transcriptional regulator by binding to heterochromatin in endothelial cells<sup>[<xref rid="R42" ref-type="bibr">42</xref>]</sup>. Intrinsic IL-33 has also been identified in Treg cells, and we observed that IL-33 significantly located in the nuclei of tumor-infiltrating Tregs. NF-&#954;B activity is of great importance in Tregs generation and maintenance<sup>[<xref rid="R43" ref-type="bibr">43</xref>,<xref rid="R44" ref-type="bibr">44</xref>]</sup>. In previous studies, intrinsic nIL-33 could interfere with the DNA-binding activity of NF-&#954;B and regulated its downstream genes transcription<sup>[<xref rid="R45" ref-type="bibr">45</xref>]</sup>, this may be the potential mechanism that IL-33<sup>+</sup> Tregs had stronger immunosuppressive capacity. However, the detailed mechanism of nIL-33 of Tregs and its molecular characteristics in PDAC needs to be further explored. Meanwhile, Xie <italic toggle="yes">et al</italic><sup>[<xref rid="R46" ref-type="bibr">46</xref>]</sup> discovered that in a tobacco smoke-induced liver cancer model, IL-33 activated the p38 MAPK pathway, which promoted both cancer stem cell expansion and Treg suppression, accelerating tumor progression. Additionally, the IL-33/SMAD signaling pathway, the HIF/IL-33/GATA3 axis, and the IL-33/COX2/PGE2 axis have all been validated as key mechanisms by which IL-33 drives tumor progression and suppresses immune responses against tumors<sup>[<xref rid="R47" ref-type="bibr">47</xref>&#8211;<xref rid="R49" ref-type="bibr">49</xref>]</sup>. Given these findings, we propose that IL-33<sup>+</sup> Tregs, a distinct Treg subtype, exert a pronounced immunosuppressive effect within tumors. This subtype likely plays a pivotal role in the immunosuppressive environment of PDAC. The consistent immunosuppressive activity observed may be due either to IL-33 enhancing the suppressive function of Tregs within the TME or to IL-33<sup>+</sup> Tregs themselves exerting a particularly strong tumor-suppressive effect.</p><p>Through comprehensive multidimensional analysis, our study established significant associations between IL-33<sup>+</sup> Treg and clinicopathological characteristics including elevated serum CA19-9 levels, microvascular invasion, and perineural invasion in PDAC. The higher CA19-9 levels, microvascular and perineural invasion reflect the aggressive malignant behavior of PDAC, which hints the potential role of IL-33<sup>+</sup> Tregs in PDAC progression. One recent study has described CA19-9 production at single-cell resolution and the dynamics of the immune atlas in terms of CA19-9, and found two high macrophage subtypes were associated with an unfavorable clinical prognosis in PDAC<sup>[<xref rid="R50" ref-type="bibr">50</xref>]</sup>. Recent studies have also shown that perineural invasion is associated with impaired immune responses<sup>[<xref rid="R51" ref-type="bibr">51</xref>,<xref rid="R52" ref-type="bibr">52</xref>]</sup>. For instance, Yang <italic toggle="yes">et al</italic><sup>[<xref rid="R51" ref-type="bibr">51</xref>]</sup> found that the perineural invasion is characterized by a reduction in CD8<sup>+</sup> T cells and a lower Th1/Th2 ratio. Additionally, we observed that a high infiltration of IL-33<sup>+</sup> Tregs is linked to poorer prognosis in PDAC patients. Historically, the academic community has long debated the role of IL-33 in PDAC, with differing views on its origins and whether it primarily promotes or suppresses tumor growth<sup>[<xref rid="R30" ref-type="bibr">30</xref>,<xref rid="R32" ref-type="bibr">32</xref>,<xref rid="R33" ref-type="bibr">33</xref>,<xref rid="R40" ref-type="bibr">40</xref>]</sup>. Our research provides new evidence that IL-33<sup>+</sup> Tregs act as adverse prognostic factors, indicating that this Treg subset, more than other IL-33 sources, plays a central role in tumor immune suppression in PDAC. In this study, we were the first to identify the distinctive prognostic role of IL-33<sup>+</sup> Tregs, which proved to be more significant than that of conventional Tregs. By stratifying patients based on the level of tumor-infiltrating IL-33<sup>+</sup> Tregs, we developed a more precise predictive model for clinical outcomes, identified a cohort with no survival benefit, irrespective of CA19-9 levels, and a specific group that would benefit from ACT. As we know, tumor differentiation and serum CA19-9 level both reflect the aggressive malignant behavior in PDAC<sup>[<xref rid="R21" ref-type="bibr">21</xref>,<xref rid="R53" ref-type="bibr">53</xref>]</sup>. Our model, which incorporates tumor differentiation and IL-33<sup>+</sup> Tregs, captures both the intrinsic tumor behavior and the immunosuppressive microenvironment, potentially offering greater accuracy than existing models that just reflect tumor malignancy. Importantly, tumor-infiltrating IL-33<sup>+</sup> Tregs emerged as a critical factor influencing the predictive accuracy of CA19-9, highlighting the interaction between the TME and tumor self-characteristics. This suggests that the immunosuppressive components may play a more dominant role than the tumor&#8217;s biological properties in driving tumor progression. By leveraging these insights, clinicians may be better equipped to identify a specific cohort whose survival is unaffected by CA19-9 levels, allowing for more personalized treatment approaches. Additionally, increasing evidence suggests that the extent of immune cell infiltration and their functional status significantly impact the effectiveness of ACT. Di Caro <italic toggle="yes">et al</italic><sup>[<xref rid="R54" ref-type="bibr">54</xref>]</sup>. found that TAMs play a pivotal role in determining the response to ACT. In our previous study, we also demonstrated that lower levels of tumor-infiltrating CD161<sup>+</sup>CD8<sup>+</sup> T cells were linked to a better response to ACT<sup>[<xref rid="R17" ref-type="bibr">17</xref>]</sup>. Building on these findings, our current study proposes IL-33<sup>+</sup> Tregs as a novel predictive marker for responsiveness to ACT, further refining the ability to tailor treatment strategies in PDAC.</p><p>However, several limitations of this study should be acknowledged. First, the retrospective, single-center design may restrict the generalizability of our findings. A larger, prospective, multicenter cohort is required to validate the robustness of these results. Additionally, the study focused on patients eligible for resection, predominantly those with stages I and II disease. To avoid potential effects on the TME, some stage III patients who had received neoadjuvant therapy for PDAC were excluded. Stage IV patients, being ineligible for surgical intervention, lacked available tumor specimens. Nevertheless, the distribution of patients across stages in our cohort is consistent with other studies<sup>[<xref rid="R25" ref-type="bibr">25</xref>,<xref rid="R55" ref-type="bibr">55</xref>,<xref rid="R56" ref-type="bibr">56</xref>]</sup>. Moreover, our research focused on the translational relevance of IL-33<sup>+</sup> Tregs, highlighting their potential clinical significance. Further studies are necessary to comprehensively understand the role of IL-33 within Tregs. Additionally, the potential involvement of IL-33<sup>+</sup> Tregs in peripheral circulation and their relationship with tumor-infiltrating IL-33<sup>+</sup> Tregs require further exploration. Investigating the potential of targeting these cells as a novel immunotherapy strategy presents a promising avenue for future research.</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>Our study highlights the significance of IL-33<sup>+</sup> Tregs as a promising biomarker for predicting both survival and therapeutic response to ACT in PDAC. Additionally, their pronounced immunosuppressive role underscores their potential as an appealing target for future immunotherapy strategies.</p></sec></body><back><ack><title>Acknowledgements</title><p>Not applicable.</p></ack><fn-group><fn fn-type="other"><p>Ning Pu, Qiangda Chen, Jiande Han, Zhihang Xu contributed equally as co-first authors of this article.</p></fn><fn fn-type="other"><p>Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.</p></fn><fn fn-type="other"><p>Supplemental Digital Content is available for this article. Direct URL citations are provided in the HTML and PDF versions of this article on the journal&#8217;s website, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="www.lww.com/international-journal-of-surgery" ext-link-type="uri">www.lww.com/international-journal-of-surgery</ext-link>.</p></fn><fn fn-type="equal"><p>Published online 10 June 2025</p></fn></fn-group><sec><title>Ethical approval</title><p>The protocol of this study has been approved by the institutional review board and ethics committee of Zhongshan Hospital, Fudan University (B2023-129). Written informed consent was obtained from individual or guardian participants. The protocol was registered in Research Registry (researchregistry11246).</p></sec><sec><title>Consent</title><p>Not applicable.</p></sec><sec><title>Sources of funding</title><p>This work was supported by grants from Shanghai Municipal Health Commission (20244Y0023, 201940019), National Natural Science Foundation of China (82103409, 82273382, 82473459), Beijing Xisike Clinical Oncology Research Foundation (Y-2022METAZQN-0003, Y-Gilead2024-PT-0002, Y-HR2022MS-0251), Shanghai &#8220;Rising Stars of Medical Talents&#8221; Youth Development Program, Open Research Fund of Key Laboratory of Gastrointestinal Cancer (Fujian Medical University), Ministry of Education (FMUGIC-202301), Fund of Fujian Provincial Key Laboratory of Translational Cancer Medicine (TCM2024-2), Program of Shanghai Academic/Technology Research Leader (23XD1400600), Shanghai Anticancer Association EYAS PROJECT (SACA-CY24B09), Youth Fund Project of Zhongshan hospital (2024ZSQN33, ZSZP202401) and Liu Liang Expert Workstation of Yunnan Province (202305AF150148).</p></sec><sec><title>Author contributions</title><p>N.P., H.Y., W.L., and L.L. contributed to funding acquisition, data acquisition, data analysis, manuscript writing, manuscript review. Q.C., J.H., and Z.X. were involved in data acquisition, data analysis, statistical analysis, manuscript writing. Z.J., T.H., Y.A., Y.X., W.G., H.W., W.W., W.W., Y.J., and J.Y. contributed to data acquisition, manuscript review. All authors read and approved the final version of the manuscript. N.P. supervised the study. L.L. is responsible for the overall content as guarantor.</p></sec><sec sec-type="COI-statement"><title>Conflicts of interest disclosure</title><p>None declared.</p></sec><sec><title>Research registration unique identifying number (UIN)</title><p>Research Registry; Intratumoral IL-33<sup>+</sup>CD4<sup>+</sup>FoxP3<sup>+</sup> regulatory T cell infiltration determines poor clinical outcomes and intensive immunoevasive contexture in patients with pancreatic cancer after surgical resection; researchregistry7046; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.researchregistry.com/browse-the-registry" ext-link-type="uri">https://www.researchregistry.com/browse-the-registry</ext-link>.</p></sec><sec><title>Guarantor</title><p>Liang Liu.</p></sec><sec><title>Provenance and peer review</title><p>Not commissioned, externally peer-reviewed.</p></sec><sec sec-type="data-availability"><title>Data availability statement</title><p>The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy and ethical restrictions.</p></sec><ref-list><title>References</title><ref id="R1"><label>[1]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siegel</surname><given-names>RL</given-names></name><name name-style="western"><surname>Giaquinto</surname><given-names>AN</given-names></name><name name-style="western"><surname>Jemal</surname><given-names>A</given-names></name></person-group>. <article-title>Cancer statistics, 2024</article-title>. <source>CA Cancer J Clin</source><year>2024</year>;<volume>74</volume>:<fpage>12</fpage>&#8211;<lpage>49</lpage>.<pub-id pub-id-type="pmid">38230766</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21820</pub-id></mixed-citation></ref><ref id="R2"><label>[2]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pu</surname><given-names>N</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S</given-names></name><name name-style="western"><surname>Bai</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>Outcomes of patients undergoing elective pancreatic surgery during COVID-19 pandemic: a multicenter, prospective cohort study</article-title>. <source>Cancer Scr Prev</source><year>2023</year>;<volume>2</volume>:<fpage>229</fpage>&#8211;<lpage>37</lpage>.</mixed-citation></ref><ref id="R3"><label>[3]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>S</given-names></name><name name-style="western"><surname>Fang</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Single cell transcriptomic analyses implicate an immunosuppressive tumor microenvironment in pancreatic cancer liver metastasis</article-title>. <source>Nat Commun</source><year>2023</year>;<volume>14</volume>:<fpage>5123</fpage>.<pub-id pub-id-type="pmid">37612267</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-023-40727-7</pub-id><pub-id pub-id-type="pmcid">PMC10447466</pub-id></mixed-citation></ref><ref id="R4"><label>[4]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>W</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Advances in screening and early diagnosis of pancreatic cancer</article-title>. <source>Cancer Scr Prev</source><year>2024</year>;<volume>3</volume>:<fpage>154</fpage>&#8211;<lpage>62</lpage>.</mixed-citation></ref><ref id="R5"><label>[5]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feig</surname><given-names>C</given-names></name><name name-style="western"><surname>Gopinathan</surname><given-names>A</given-names></name><name name-style="western"><surname>Neesse</surname><given-names>A</given-names></name><name name-style="western"><surname>Chan</surname><given-names>DS</given-names></name><name name-style="western"><surname>Cook</surname><given-names>N</given-names></name><name name-style="western"><surname>Tuveson</surname><given-names>DA</given-names></name></person-group>. <article-title>The pancreas cancer microenvironment</article-title>. <source>Clin Cancer Res</source><year>2012</year>;<volume>18</volume>:<fpage>4266</fpage>&#8211;<lpage>76</lpage>.<pub-id pub-id-type="pmid">22896693</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-11-3114</pub-id><pub-id pub-id-type="pmcid">PMC3442232</pub-id></mixed-citation></ref><ref id="R6"><label>[6]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hori</surname><given-names>S</given-names></name><name name-style="western"><surname>Nomura</surname><given-names>T</given-names></name><name name-style="western"><surname>Sakaguchi</surname><given-names>S</given-names></name></person-group>. <article-title>Control of regulatory T cell development by the transcription factor Foxp3</article-title>. <source>Sci</source><year>2003</year>;<volume>299</volume>:<fpage>1057</fpage>&#8211;<lpage>61</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1079490</pub-id><pub-id pub-id-type="pmid">12522256</pub-id></mixed-citation></ref><ref id="R7"><label>[7]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumagai</surname><given-names>S</given-names></name><name name-style="western"><surname>Itahashi</surname><given-names>K</given-names></name><name name-style="western"><surname>Nishikawa</surname><given-names>H</given-names></name></person-group>. <article-title>Regulatory T cell-mediated immunosuppression orchestrated by cancer: towards an immuno-genomic paradigm for precision medicine</article-title>. <source>Nat Rev Clin Oncol</source><year>2024</year>;<volume>21</volume>:<fpage>337</fpage>&#8211;<lpage>53</lpage>.<pub-id pub-id-type="pmid">38424196</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41571-024-00870-6</pub-id></mixed-citation></ref><ref id="R8"><label>[8]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pu</surname><given-names>N</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G</given-names></name><name name-style="western"><surname>Yin</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>CD25 and TGF-beta blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer</article-title>. <source>J Transl Med</source><year>2018</year>;<volume>16</volume>:<fpage>294</fpage>.<pub-id pub-id-type="pmid">30359281</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12967-018-1673-6</pub-id><pub-id pub-id-type="pmcid">PMC6203282</pub-id></mixed-citation></ref><ref id="R9"><label>[9]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Q</given-names></name><name name-style="western"><surname>Yin</surname><given-names>H</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Prognostic value of tumor-associated N1/N2 neutrophil plasticity in patients following radical resection of pancreas ductal adenocarcinoma</article-title>. <source>J Immunother Cancer</source><year>2022</year>;<volume>10</volume>:<fpage>e005798</fpage>.<pub-id pub-id-type="pmid">36600557</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jitc-2022-005798</pub-id><pub-id pub-id-type="pmcid">PMC9730407</pub-id></mixed-citation></ref><ref id="R10"><label>[10]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hatzioannou</surname><given-names>A</given-names></name><name name-style="western"><surname>Banos</surname><given-names>A</given-names></name><name name-style="western"><surname>Sakelaropoulos</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>An intrinsic role of IL-33 in T(reg) cell-mediated tumor immunoevasion</article-title>. <source>Nat Immunol</source><year>2020</year>;<volume>21</volume>:<fpage>75</fpage>&#8211;<lpage>85</lpage>.<pub-id pub-id-type="pmid">31844326</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41590-019-0555-2</pub-id><pub-id pub-id-type="pmcid">PMC7030950</pub-id></mixed-citation></ref><ref id="R11"><label>[11]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baekkevold</surname><given-names>ES</given-names></name><name name-style="western"><surname>Roussigne</surname><given-names>M</given-names></name><name name-style="western"><surname>Yamanaka</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules</article-title>. <source>Am J Pathol</source><year>2003</year>;<volume>163</volume>:<fpage>69</fpage>&#8211;<lpage>79</lpage>.<pub-id pub-id-type="pmid">12819012</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0002-9440(10)63631-0</pub-id><pub-id pub-id-type="pmcid">PMC1868188</pub-id></mixed-citation></ref><ref id="R12"><label>[12]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cayrol</surname><given-names>C</given-names></name><name name-style="western"><surname>Girard</surname><given-names>JP</given-names></name></person-group>. <article-title>Interleukin-33 (IL-33): a nuclear cytokine from the IL-1 family</article-title>. <source>Immunol Rev</source><year>2018</year>;<volume>281</volume>:<fpage>154</fpage>&#8211;<lpage>68</lpage>.<pub-id pub-id-type="pmid">29247993</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/imr.12619</pub-id></mixed-citation></ref><ref id="R13"><label>[13]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kakkar</surname><given-names>R</given-names></name><name name-style="western"><surname>Hei</surname><given-names>H</given-names></name><name name-style="western"><surname>Dobner</surname><given-names>S</given-names></name><name name-style="western"><surname>Lee</surname><given-names>RT</given-names></name></person-group>. <article-title>Interleukin 33 as a mechanically responsive cytokine secreted by living cells</article-title>. <source>J Biol Chem</source><year>2012</year>;<volume>287</volume>:<fpage>6941</fpage>&#8211;<lpage>48</lpage>.<pub-id pub-id-type="pmid">22215666</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M111.298703</pub-id><pub-id pub-id-type="pmcid">PMC3307313</pub-id></mixed-citation></ref><ref id="R14"><label>[14]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liew</surname><given-names>FY</given-names></name><name name-style="western"><surname>Girard</surname><given-names>JP</given-names></name><name name-style="western"><surname>Turnquist</surname><given-names>HR</given-names></name></person-group>. <article-title>Interleukin-33 in health and disease</article-title>. <source>Nat Rev Immunol</source><year>2016</year>;<volume>16</volume>:<fpage>676</fpage>&#8211;<lpage>89</lpage>.<pub-id pub-id-type="pmid">27640624</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nri.2016.95</pub-id></mixed-citation></ref><ref id="R15"><label>[15]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kouzaki</surname><given-names>H</given-names></name><name name-style="western"><surname>Iijima</surname><given-names>K</given-names></name><name name-style="western"><surname>Kobayashi</surname><given-names>T</given-names></name><name name-style="western"><surname>O&#8217;Grady</surname><given-names>SM</given-names></name><name name-style="western"><surname>Kita</surname><given-names>H</given-names></name></person-group>. <article-title>The danger signal, extracellular ATP, is a sensor for an airborne allergen and triggers IL-33 release and innate Th2-type responses</article-title>. <source>J Immunol</source><year>2011</year>;<volume>186</volume>:<fpage>4375</fpage>&#8211;<lpage>87</lpage>.<pub-id pub-id-type="pmid">21357533</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.1003020</pub-id><pub-id pub-id-type="pmcid">PMC3062674</pub-id></mixed-citation></ref><ref id="R16"><label>[16]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schiering</surname><given-names>C</given-names></name><name name-style="western"><surname>Krausgruber</surname><given-names>T</given-names></name><name name-style="western"><surname>Chomka</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>The alarmin IL-33 promotes regulatory T-cell function in the intestine</article-title>. <source>Nature</source><year>2014</year>;<volume>513</volume>:<fpage>564</fpage>&#8211;<lpage>68</lpage>.<pub-id pub-id-type="pmid">25043027</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature13577</pub-id><pub-id pub-id-type="pmcid">PMC4339042</pub-id></mixed-citation></ref><ref id="R17"><label>[17]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Q</given-names></name><name name-style="western"><surname>Yin</surname><given-names>H</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>Poor clinical outcomes and immunoevasive contexture in CD161(+)CD8(+) T cells barren human pancreatic cancer</article-title>. <source>J Immunother Cancer</source><year>2024</year>;<volume>12</volume>:<fpage>e008694</fpage>.<pub-id pub-id-type="pmid">38531664</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jitc-2023-008694</pub-id><pub-id pub-id-type="pmcid">PMC10966787</pub-id></mixed-citation></ref><ref id="R18"><label>[18]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agha</surname><given-names>RA</given-names></name><name name-style="western"><surname>Mathew</surname><given-names>G</given-names></name><name name-style="western"><surname>Rashid</surname><given-names>R</given-names></name><etal/></person-group>. <collab>STROCSS Group</collab>. <article-title>Revised Strengthening the Reporting of Cohort, Cross-Sectional and Case-Control Studies in Surgery (STROCSS) guideline: an update for the age of artificial intelligence</article-title>. <source>Prem J Sci</source><year>2025</year>:<fpage>100081</fpage>.</mixed-citation></ref><ref id="R19"><label>[19]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pu</surname><given-names>N</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Q</given-names></name><name name-style="western"><surname>Yin</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Identification of an immune-related BAT signature for predicting adjuvant chemotherapy response and overall survival in patients with resected ductal adenocarcinoma of the pancreas</article-title>. <source>J Gastrointest Surg</source><year>2022</year>;<volume>26</volume>:<fpage>869</fpage>&#8211;<lpage>86</lpage>.<pub-id pub-id-type="pmid">35059985</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11605-021-05232-6</pub-id></mixed-citation></ref><ref id="R20"><label>[20]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yin</surname><given-names>H</given-names></name><name name-style="western"><surname>Pu</surname><given-names>N</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Q</given-names></name><etal/></person-group>. <article-title>Gut-derived lipopolysaccharide remodels tumoral microenvironment and synergizes with PD-L1 checkpoint blockade via TLR4/MyD88/AKT/NF-kappaB pathway in pancreatic cancer</article-title>. <source>Cell Death Dis</source><year>2021</year>;<volume>12</volume>:<fpage>1033</fpage>.<pub-id pub-id-type="pmid">34718325</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41419-021-04293-4</pub-id><pub-id pub-id-type="pmcid">PMC8557215</pub-id></mixed-citation></ref><ref id="R21"><label>[21]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>B</given-names></name><name name-style="western"><surname>Yin</surname><given-names>X</given-names></name><name name-style="western"><surname>Ding</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>Combined utility of Ki-67 index and tumor grade to stratify patients with pancreatic ductal adenocarcinoma who underwent upfront surgery</article-title>. <source>BMC Surg</source><year>2023</year>;<volume>23</volume>:<fpage>370</fpage>.<pub-id pub-id-type="pmid">38066512</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12893-023-02256-4</pub-id><pub-id pub-id-type="pmcid">PMC10704770</pub-id></mixed-citation></ref><ref id="R22"><label>[22]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Oosten</surname><given-names>AF</given-names></name><name name-style="western"><surname>Groot</surname><given-names>VP</given-names></name><name name-style="western"><surname>Dorland</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Dynamics of serum CA19-9 in patients undergoing pancreatic cancer resection</article-title>. <source>Ann Surg</source><year>2024</year>;<volume>279</volume>:<fpage>493</fpage>&#8211;<lpage>500</lpage>.<pub-id pub-id-type="pmid">37389896</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/SLA.0000000000005977</pub-id></mixed-citation></ref><ref id="R23"><label>[23]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seelen</surname><given-names>LWF</given-names></name><name name-style="western"><surname>Doppenberg</surname><given-names>D</given-names></name><name name-style="western"><surname>Stoop</surname><given-names>TF</given-names></name><etal/></person-group>. <article-title>Minimum and optimal CA19-9 response after two months induction chemotherapy in patients with locally advanced pancreatic cancer: a nationwide multicenter study</article-title>. <source>Ann Surg</source><year>2024</year>;<volume>279</volume>:<fpage>832</fpage>&#8211;<lpage>41</lpage>.<pub-id pub-id-type="pmid">37477009</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/SLA.0000000000006021</pub-id></mixed-citation></ref><ref id="R24"><label>[24]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dias Costa</surname><given-names>A</given-names></name><name name-style="western"><surname>Vayrynen</surname><given-names>SA</given-names></name><name name-style="western"><surname>Chawla</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Neoadjuvant chemotherapy is associated with altered immune cell infiltration and an anti-tumorigenic microenvironment in resected pancreatic cancer</article-title>. <source>Clin Cancer Res</source><year>2022</year>;<volume>28</volume>:<fpage>5167</fpage>&#8211;<lpage>79</lpage>.<pub-id pub-id-type="pmid">36129461</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-22-1125</pub-id><pub-id pub-id-type="pmcid">PMC9999119</pub-id></mixed-citation></ref><ref id="R25"><label>[25]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>H</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Mo</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>The spatial coexistence of TIGIT/CD155 defines poorer survival and resistance to adjuvant chemotherapy in pancreatic ductal adenocarcinoma</article-title>. <source>Theranostics</source><year>2023</year>;<volume>13</volume>:<fpage>4601</fpage>&#8211;<lpage>14</lpage>.<pub-id pub-id-type="pmid">37649613</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/thno.86547</pub-id><pub-id pub-id-type="pmcid">PMC10465224</pub-id></mixed-citation></ref><ref id="R26"><label>[26]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>P</given-names></name><name name-style="western"><surname>Liu</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Enhancing chemotherapy for pancreatic cancer through efficient and sustained tumor microenvironment remodeling with a fibroblast-targeted nanosystem</article-title>. <source>J Control Release</source><year>2023</year>;<volume>361</volume>:<fpage>161</fpage>&#8211;<lpage>77</lpage>.<pub-id pub-id-type="pmid">37536546</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2023.07.061</pub-id></mixed-citation></ref><ref id="R27"><label>[27]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chand</surname><given-names>S</given-names></name><name name-style="western"><surname>O&#8217;Hayer</surname><given-names>K</given-names></name><name name-style="western"><surname>Blanco</surname><given-names>FF</given-names></name><name name-style="western"><surname>Winter</surname><given-names>JM</given-names></name><name name-style="western"><surname>Brody</surname><given-names>JR</given-names></name></person-group>. <article-title>The landscape of pancreatic cancer therapeutic resistance mechanisms</article-title>. <source>Int J Biol Sci</source><year>2016</year>;<volume>12</volume>:<fpage>273</fpage>&#8211;<lpage>82</lpage>.<pub-id pub-id-type="pmid">26929734</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/ijbs.14951</pub-id><pub-id pub-id-type="pmcid">PMC4753156</pub-id></mixed-citation></ref><ref id="R28"><label>[28]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mantovani</surname><given-names>A</given-names></name><name name-style="western"><surname>Dinarello</surname><given-names>CA</given-names></name><name name-style="western"><surname>Molgora</surname><given-names>M</given-names></name><name name-style="western"><surname>Garlanda</surname><given-names>C</given-names></name></person-group>. <article-title>Interleukin-1 and related cytokines in the regulation of inflammation and immunity</article-title>. <source>Immunity</source><year>2019</year>;<volume>50</volume>:<fpage>778</fpage>&#8211;<lpage>95</lpage>.<pub-id pub-id-type="pmid">30995499</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2019.03.012</pub-id><pub-id pub-id-type="pmcid">PMC7174020</pub-id></mixed-citation></ref><ref id="R29"><label>[29]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taniguchi</surname><given-names>S</given-names></name><name name-style="western"><surname>Elhance</surname><given-names>A</given-names></name><name name-style="western"><surname>Van Duzer</surname><given-names>A</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>S</given-names></name><name name-style="western"><surname>Leitenberger</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Oshimori</surname><given-names>N</given-names></name></person-group>. <article-title>Tumor-initiating cells establish an IL-33-TGF-beta niche signaling loop to promote cancer progression</article-title>. <source>Sci</source><year>2020</year>;<volume>369</volume>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aay1813</pub-id><pub-id pub-id-type="pmcid">PMC10870826</pub-id><pub-id pub-id-type="pmid">32675345</pub-id></mixed-citation></ref><ref id="R30"><label>[30]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alam</surname><given-names>A</given-names></name><name name-style="western"><surname>Levanduski</surname><given-names>E</given-names></name><name name-style="western"><surname>Denz</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Fungal mycobiome drives IL-33 secretion and type 2 immunity in pancreatic cancer</article-title>. <source>Cancer Cell</source><year>2022</year>;<volume>40</volume>:<fpage>153</fpage>&#8211;<lpage>67e11</lpage>.<pub-id pub-id-type="pmid">35120601</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ccell.2022.01.003</pub-id><pub-id pub-id-type="pmcid">PMC8847236</pub-id></mixed-citation></ref><ref id="R31"><label>[31]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alonso-Curbelo</surname><given-names>D</given-names></name><name name-style="western"><surname>Ho</surname><given-names>Y-J</given-names></name><name name-style="western"><surname>Burdziak</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>A gene-environment-induced epigenetic program initiates tumorigenesis</article-title>. <source>Nature</source><year>2021</year>;<volume>590</volume>:<fpage>642</fpage>&#8211;<lpage>48</lpage>.<pub-id pub-id-type="pmid">33536616</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-03147-x</pub-id><pub-id pub-id-type="pmcid">PMC8482641</pub-id></mixed-citation></ref><ref id="R32"><label>[32]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nishida</surname><given-names>A</given-names></name><name name-style="western"><surname>Andoh</surname><given-names>A</given-names></name><name name-style="western"><surname>Imaeda</surname><given-names>H</given-names></name><name name-style="western"><surname>Inatomi</surname><given-names>O</given-names></name><name name-style="western"><surname>Shiomi</surname><given-names>H</given-names></name><name name-style="western"><surname>Fujiyama</surname><given-names>Y</given-names></name></person-group>. <article-title>Expression of interleukin 1-like cytokine interleukin 33 and its receptor complex (ST2L and IL1RAcP) in human pancreatic myofibroblasts</article-title>. <source>Gut</source><year>2010</year>;<volume>59</volume>:<fpage>531</fpage>&#8211;<lpage>41</lpage>.<pub-id pub-id-type="pmid">19996325</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/gut.2009.193599</pub-id></mixed-citation></ref><ref id="R33"><label>[33]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Donahue</surname><given-names>KL</given-names></name><name name-style="western"><surname>Watkoske</surname><given-names>HR</given-names></name><name name-style="western"><surname>Kadiyala</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Oncogenic KRAS-dependent stromal interleukin-33 directs the pancreatic microenvironment to promote tumor growth</article-title>. <source>Cancer Discov</source><year>2024</year>;<volume>14</volume>:<fpage>1964</fpage>&#8211;<lpage>89</lpage>.<pub-id pub-id-type="pmid">38958646</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/2159-8290.CD-24-0100</pub-id><pub-id pub-id-type="pmcid">PMC11450371</pub-id></mixed-citation></ref><ref id="R34"><label>[34]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schmitz</surname><given-names>J</given-names></name><name name-style="western"><surname>Owyang</surname><given-names>A</given-names></name><name name-style="western"><surname>Oldham</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines</article-title>. <source>Immunity</source><year>2005</year>;<volume>23</volume>:<fpage>479</fpage>&#8211;<lpage>90</lpage>.<pub-id pub-id-type="pmid">16286016</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2005.09.015</pub-id></mixed-citation></ref><ref id="R35"><label>[35]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akimoto</surname><given-names>M</given-names></name><name name-style="western"><surname>Maruyama</surname><given-names>R</given-names></name><name name-style="western"><surname>Takamaru</surname><given-names>H</given-names></name><name name-style="western"><surname>Ochiya</surname><given-names>T</given-names></name><name name-style="western"><surname>Takenaga</surname><given-names>K</given-names></name></person-group>. <article-title>Soluble IL-33 receptor sST2 inhibits colorectal cancer malignant growth by modifying the tumour microenvironment</article-title>. <source>Nat Commun</source><year>2016</year>;<volume>7</volume>:<fpage>13589</fpage>.<pub-id pub-id-type="pmid">27882929</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncomms13589</pub-id><pub-id pub-id-type="pmcid">PMC5123057</pub-id></mixed-citation></ref><ref id="R36"><label>[36]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lv</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tian</surname><given-names>W</given-names></name><name name-style="western"><surname>Teng</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Tumor-infiltrating mast cells stimulate ICOS(+) regulatory T cells through an IL-33 and IL-2 axis to promote gastric cancer progression</article-title>. <source>J Adv Res</source><year>2024</year>;<volume>57</volume>:<fpage>149</fpage>&#8211;<lpage>62</lpage>.<pub-id pub-id-type="pmid">37086778</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jare.2023.04.013</pub-id><pub-id pub-id-type="pmcid">PMC10918354</pub-id></mixed-citation></ref><ref id="R37"><label>[37]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liguori</surname><given-names>M</given-names></name><name name-style="western"><surname>Digifico</surname><given-names>E</given-names></name><name name-style="western"><surname>Vacchini</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>The soluble glycoprotein NMB (GPNMB) produced by macrophages induces cancer stemness and metastasis via CD44 and IL-33</article-title>. <source>Cell Mol Immunol</source><year>2021</year>;<volume>18</volume>:<fpage>711</fpage>&#8211;<lpage>22</lpage>.<pub-id pub-id-type="pmid">32728200</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41423-020-0501-0</pub-id><pub-id pub-id-type="pmcid">PMC8027814</pub-id></mixed-citation></ref><ref id="R38"><label>[38]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andersson</surname><given-names>P</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hosaka</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Molecular mechanisms of IL-33-mediated stromal interactions in cancer metastasis</article-title>. <source>JCI Insight</source><year>2018</year>;<volume>3</volume>:<fpage>e122375</fpage>.<pub-id pub-id-type="pmid">30333314</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/jci.insight.122375</pub-id><pub-id pub-id-type="pmcid">PMC6237443</pub-id></mixed-citation></ref><ref id="R39"><label>[39]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>M</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name><name name-style="western"><surname>Di</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Alarmin IL-33 orchestrates antitumoral T cell responses to enhance sensitivity to 5-fluorouracil in colorectal cancer</article-title>. <source>Theranostics</source><year>2023</year>;<volume>13</volume>:<fpage>1649</fpage>&#8211;<lpage>68</lpage>.<pub-id pub-id-type="pmid">37056569</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/thno.80483</pub-id><pub-id pub-id-type="pmcid">PMC10086207</pub-id></mixed-citation></ref><ref id="R40"><label>[40]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dixit</surname><given-names>A</given-names></name><name name-style="western"><surname>Sarver</surname><given-names>A</given-names></name><name name-style="western"><surname>Zettervall</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Targeting TNF-alpha-producing macrophages activates antitumor immunity in pancreatic cancer via IL-33 signaling</article-title>. <source>JCI Insight</source><year>2022</year>;<volume>7</volume>:<fpage>e153242</fpage>.<pub-id pub-id-type="pmid">36256464</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/jci.insight.153242</pub-id><pub-id pub-id-type="pmcid">PMC9746819</pub-id></mixed-citation></ref><ref id="R41"><label>[41]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dikiy</surname><given-names>S</given-names></name><name name-style="western"><surname>Rudensky</surname><given-names>AY</given-names></name></person-group>. <article-title>Principles of regulatory T cell function</article-title>. <source>Immunity</source><year>2023</year>;<volume>56</volume>:<fpage>240</fpage>&#8211;<lpage>55</lpage>.<pub-id pub-id-type="pmid">36792571</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2023.01.004</pub-id></mixed-citation></ref><ref id="R42"><label>[42]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carriere</surname><given-names>V</given-names></name><name name-style="western"><surname>Roussel</surname><given-names>L</given-names></name><name name-style="western"><surname>Ortega</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo</article-title>. <source>Proc Natl Acad Sci U S A</source><year>2007</year>;<volume>104</volume>:<fpage>282</fpage>&#8211;<lpage>87</lpage>.<pub-id pub-id-type="pmid">17185418</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0606854104</pub-id><pub-id pub-id-type="pmcid">PMC1765450</pub-id></mixed-citation></ref><ref id="R43"><label>[43]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oh</surname><given-names>H</given-names></name><name name-style="western"><surname>Grinberg-Bleyer</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liao</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>An NF-kappaB transcription-factor-dependent lineage-specific transcriptional program promotes regulatory T cell identity and function</article-title>. <source>Immunity</source><year>2017</year>;<volume>47</volume>:<fpage>450</fpage>&#8211;<lpage>65e5</lpage>.<pub-id pub-id-type="pmid">28889947</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2017.08.010</pub-id><pub-id pub-id-type="pmcid">PMC5679261</pub-id></mixed-citation></ref><ref id="R44"><label>[44]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grinberg-Bleyer</surname><given-names>Y</given-names></name><name name-style="western"><surname>Oh</surname><given-names>H</given-names></name><name name-style="western"><surname>Desrichard</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>NF-kappaB c-Rel is crucial for the regulatory T cell immune checkpoint in cancer</article-title>. <source>Cell</source><year>2017</year>;<volume>170</volume>:<fpage>1096</fpage>&#8211;<lpage>108e13</lpage>.<pub-id pub-id-type="pmid">28886380</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2017.08.004</pub-id><pub-id pub-id-type="pmcid">PMC5633372</pub-id></mixed-citation></ref><ref id="R45"><label>[45]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ali</surname><given-names>S</given-names></name><name name-style="western"><surname>Mohs</surname><given-names>A</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>The dual function cytokine IL-33 interacts with the transcription factor NF-kappaB to dampen NF-kappaB-stimulated gene transcription</article-title>. <source>J Immunol</source><year>2011</year>;<volume>187</volume>:<fpage>1609</fpage>&#8211;<lpage>16</lpage>.<pub-id pub-id-type="pmid">21734074</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.1003080</pub-id></mixed-citation></ref><ref id="R46"><label>[46]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>Tobacco smoke induced hepatic cancer stem cell-like properties through IL-33/p38 pathway</article-title>. <source>J Exp Clin Cancer Res</source><year>2019</year>;<volume>38</volume>:<fpage>39</fpage>.<pub-id pub-id-type="pmid">30691509</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13046-019-1052-z</pub-id><pub-id pub-id-type="pmcid">PMC6350284</pub-id></mixed-citation></ref><ref id="R47"><label>[47]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>JH</given-names></name><name name-style="western"><surname>Ameri</surname><given-names>AH</given-names></name><name name-style="western"><surname>Dempsey</surname><given-names>KE</given-names></name><etal/></person-group>. <article-title>Nuclear IL-33/SMAD signaling axis promotes cancer development in chronic inflammation</article-title>. <source>EMBO J</source><year>2021</year>;<volume>40</volume>:<fpage>e106151</fpage>.<pub-id pub-id-type="pmid">33616251</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15252/embj.2020106151</pub-id><pub-id pub-id-type="pmcid">PMC8013835</pub-id></mixed-citation></ref><ref id="R48"><label>[48]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akimoto</surname><given-names>M</given-names></name><name name-style="western"><surname>Susa</surname><given-names>T</given-names></name><name name-style="western"><surname>Okudaira</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Hypoxia induces downregulation of the tumor-suppressive sST2 in colorectal cancer cells via the HIF-nuclear IL-33-GATA3 pathway</article-title>. <source>Proc Natl Acad Sci U S A</source><year>2023</year>;<volume>120</volume>:<fpage>e2218033120</fpage>.<pub-id pub-id-type="pmid">37094129</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.2218033120</pub-id><pub-id pub-id-type="pmcid">PMC10160999</pub-id></mixed-citation></ref><ref id="R49"><label>[49]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shi</surname><given-names>J</given-names></name><name name-style="western"><surname>Qi</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>IL-33 facilitates proliferation of colorectal cancer dependent on COX2/PGE(2)</article-title>. <source>J Exp Clin Cancer Res</source><year>2018</year>;<volume>37</volume>:<fpage>196</fpage>.<pub-id pub-id-type="pmid">30119635</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13046-018-0839-7</pub-id><pub-id pub-id-type="pmcid">PMC6098640</pub-id></mixed-citation></ref><ref id="R50"><label>[50]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>D</given-names></name><name name-style="western"><surname>Cui</surname><given-names>F</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Single-cell RNA sequencing reveals the process of CA19-9 production and dynamics of the immune microenvironment between CA19-9 (+) and CA19-9 (-) PDAC</article-title>. <source>Chin Med J (Engl)</source><year>2024</year>;<volume>137</volume>:<fpage>2415</fpage>-<lpage>28</lpage>.<pub-id pub-id-type="pmid">38816396</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CM9.0000000000003130</pub-id><pub-id pub-id-type="pmcid">PMC11479433</pub-id></mixed-citation></ref><ref id="R51"><label>[51]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>M-W</given-names></name><name name-style="western"><surname>Tao</surname><given-names>L-Y</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y-S</given-names></name><etal/></person-group>. <article-title>Perineural invasion reprograms the immune microenvironment through cholinergic signaling in pancreatic ductal adenocarcinoma</article-title>. <source>Cancer Res</source><year>2020</year>;<volume>80</volume>:<fpage>1991</fpage>&#8211;<lpage>2003</lpage>.<pub-id pub-id-type="pmid">32098780</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-19-2689</pub-id></mixed-citation></ref><ref id="R52"><label>[52]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhai</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>Predicting response to immunotherapy in gastric cancer via assessing perineural invasion-mediated inflammation in tumor microenvironment</article-title>. <source>J Exp Clin Cancer Res</source><year>2023</year>;<volume>42</volume>:<fpage>206</fpage>.<pub-id pub-id-type="pmid">37563649</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13046-023-02730-0</pub-id><pub-id pub-id-type="pmcid">PMC10416472</pub-id></mixed-citation></ref><ref id="R53"><label>[53]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sumiyoshi</surname><given-names>T</given-names></name><name name-style="western"><surname>Uemura</surname><given-names>K</given-names></name><name name-style="western"><surname>Shintakuya</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Clinical utility of the combined use of CA19-9 and DUPAN-2 in pancreatic adenocarcinoma</article-title>. <source>Ann Surg Oncol</source><year>2024</year>;<volume>31</volume>:<fpage>4665</fpage>&#8211;<lpage>72</lpage>.<pub-id pub-id-type="pmid">38652196</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1245/s10434-024-15221-z</pub-id><pub-id pub-id-type="pmcid">PMC11164736</pub-id></mixed-citation></ref><ref id="R54"><label>[54]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Di Caro</surname><given-names>G</given-names></name><name name-style="western"><surname>Cortese</surname><given-names>N</given-names></name><name name-style="western"><surname>Castino</surname><given-names>GF</given-names></name><etal/></person-group>. <article-title>Dual prognostic significance of tumour-associated macrophages in human pancreatic adenocarcinoma treated or untreated with chemotherapy</article-title>. <source>Gut</source><year>2016</year>;<volume>65</volume>:<fpage>1710</fpage>&#8211;<lpage>20</lpage>.<pub-id pub-id-type="pmid">26156960</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/gutjnl-2015-309193</pub-id></mixed-citation></ref><ref id="R55"><label>[55]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carstens</surname><given-names>JL</given-names></name><name name-style="western"><surname>Correa de Sampaio</surname><given-names>P</given-names></name><name name-style="western"><surname>Yang</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer</article-title>. <source>Nat Commun</source><year>2017</year>;<volume>8</volume>:<fpage>15095</fpage>.<pub-id pub-id-type="pmid">28447602</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncomms15095</pub-id><pub-id pub-id-type="pmcid">PMC5414182</pub-id></mixed-citation></ref><ref id="R56"><label>[56]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Balachandran</surname><given-names>VP</given-names></name><name name-style="western"><surname>Luksza</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>JN</given-names></name><etal/></person-group>. <article-title>Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer</article-title>. <source>Nature</source><year>2017</year>;<volume>551</volume>:<fpage>512</fpage>&#8211;<lpage>16</lpage>.<pub-id pub-id-type="pmid">29132146</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature24462</pub-id><pub-id pub-id-type="pmcid">PMC6145146</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>